莪术油干预肺纤维化上皮细胞转分化的实验研究
|
摘要
研究背景及目的
肺纤维化是指由多种病因引起的具有相似病理过程的一类弥漫性肺间质疾病,常发生在肺泡,早期有肺泡结构破坏和弥漫性肺泡炎,继后出现细胞外基质过度沉积,并逐渐演变为弥漫性肺间质纤维化,是肺脏损伤的结果。病人多死于进行性加重的肺纤维化所致的呼吸衰竭。在临床上又以特发性肺纤维化(IPF)最为常见。随着污染、环境恶化及药物等因素的影响,发病人数有逐年增加的趋势,但其作用机制尚不清楚,肺泡上皮细胞发生了上皮细胞间质转化可能是肺纤维化的机制之一。本实验室在前期研究中医药防治器官纤维化中发现莪术具有抗肺纤维化的药理活性。莪术油是莪术中有效提取部位,研究表明其能抑制体外培养细胞的增殖和凋亡。但是莪术油抗肺纤维化的细胞和分子调控机理目前还不清楚。为阐明莪术油对IPF的作用及可能的作用机制,本研究以博来霉素诱导的特发性肺纤维化小鼠和人肺Ⅱ型上皮细胞A549为模型,研究莪术油对特发性肺纤维化小鼠和A549细胞增殖的作用,并初步探讨了其抑制肺纤维化的机制。
研究方法及结果
1药物中成份鉴定及含量测定
1.1方法本实验以莪术油为研究对象,利用气相色谱-质谱联用技术(GC-MS)对其化学成份进行分析。莪术油样品在GC-MS仪进样后,利用Nist98标准质谱图库及相关标准品进行对照,鉴定其结构,所得结果以相对保留时间和峰面积所占百分比表示。
1.2结果共鉴定色谱峰23个,其中单峰面积占总峰面积大于10%的峰有三个单峰面积占总峰面积在5-10%的峰有三个；在23个化合物中有广泛抗肿瘤活性的p-榄香烯和莪术醇。
2整体实验评价莪术油对特发性肺纤维化小鼠的效果及作用机制
2.1方法①IR小鼠96只,随机分为4组：模型组(BLM)、莪术油中剂量组(OilM)、莪术油高剂量组(Oil H)及假手术组(Sham).模型组(BLM)、莪术油中剂量组(Oil M)、莪术油高剂量组(Oil H)经气管内注入博莱霉素(0.05 U/只)诱导肺纤维化,随即分别每日腹腔注射生理盐水和不同剂量莪术油(Oil M按100 mg·kg-1剂量给药,Oil H按200 mg·kg-1剂量给药)；假手术组(Sham)以生理盐水代替。各组动物均于气管内灌药后第7、14、28天分别处死8只,取肺组织。②HE染色,光镜下观察各组小鼠肺组织,进行肺泡炎、肺纤维化的分级。③用免疫组化方法和Western blotting检测各组小鼠肺内Ⅰ型胶原、Ⅲ型、TGF-β1、Smad3、Cat B、Cat D和Cat K的表达,并用图像分析软件检测各组的光密度。④实时荧光PCR法检测各组Cat B、Cat D、Cat K和Cat S的表达。⑤酶法检测肺组织匀浆中羟脯氨酸含量。
2.2结果
HE染色显示,假手术组肺泡结构完整、清晰,肺泡腔内无明显渗出物；模型组纤维化程度明显,在支气管周围有大片实变区,肺泡壁异常增厚,肺泡结构紊乱,腔内有渗出物,纤维化程度随时间的进展而加深加重；莪术油各剂量组肺泡结构较为清晰,在支气管周围有局部纤维化,肺泡间隔增厚,较模型组有所减轻。
Mallory染色显示,假手术组小鼠肺肺切片中胶原层在支气管壁周围较薄,肺泡区散在；模型组肺间质、肺泡区、支气管、血管周围胶原纤维明显增多,并向间质沉积,增宽的肺泡间隔蓝色纤维增多尤为明显；两个治疗组的胶原沉积低于模型组。
羟脯氨酸测定结果表明,模型组小鼠肺组织匀浆中的含量明显升高,莪术油高、中剂量组均降低其的含量,以第7天的作用最为明显。
胶原免疫组化结果表明,Ⅰ型胶原主要表达于肺间质,随纤维化的进展加深加重,大量的Ⅰ型胶原在肺泡区沉积,破坏了肺泡的正常结构,两个治疗组肺切片中Ⅰ型胶原的沉积均较模型组的下降。Ⅲ型胶原主要表达于血管和支气管上皮,以第7天时的表达量最高,随时间延长肺组织中沉积的Ⅲ型胶原逐渐减少,到第28天时,Ⅲ型胶原的表达量接近正常水平。与假手术组相比,模型组Ⅲ型胶原的含量均升高,以第7天的表达量最高,14天次之,28天时的含量最低。两个治疗组在一定程度上降低Ⅲ型胶原在肺组织中的沉积。
上皮细胞转分化相关蛋白及组织蛋白酶活性相关检测结果表明,特发性肺纤维化小鼠肺上皮细胞经历了上皮细胞间质转化,TGF-β1显著活化,促使α-SMA在肺泡区表达增强,下游信号分子Smad3表达增强,活化的Cat K、CatB和Cat S促使胶原降解,活化的Cat D加重了肺纤维化。两个治疗组较模型组中信号分子表达减弱,Cat K、Cat B和Cat S信号表达增强,Cat D的活化被抑制。
3莪术油对A549细胞增殖抑制机理
3.1方法本实验通过体外培养A549细胞,莪术油干预后,测定其对细胞增殖、细胞周期、细胞凋亡、胶原沉积及组织蛋白酶活性等方面的影响。
3.2结果莪术油剂量为80 mg·mL-1时,细胞阻滞于S期,并伴随凋亡和坏死事件的发生；Cat D、Cat K的表达均上调。
结论
1使用GC-MS分析技术,对莪术油进行了化学成分研究,分离了23种化学结构,其中包含广泛报道的具有肿瘤抑制活性的p-榄香烯、莪术醇。
2莪术油能改善特发性肺纤维化小鼠炎性细胞浸润,维持肺泡结构正常,以利于肺内气体交换,提高生存率；细胞外基质以Ⅰ型胶原的沉积为主,伴有Ⅲ型胶原的增生。
3博来霉素诱导的肺纤维化模型中,上皮细胞经历了间质转化,莪术油能抑制纤维形成期上皮细胞的间质转化,从而有效的拮抗肺组织纤维化。
4半胱氨酸组织蛋白酶K、S、B参与纤维化小鼠肺组织细胞外基质的重构,但其作用时间受到活化的TGF-β1的抑制而延后；莪术油能部分抑制TGF-β1免疫活性,提高纤维化肺组织中半胱氨酸组织蛋白酶K、S和B mRNA水平,降低大量沉积的细胞外基质而抑制纤维化的发展。组织蛋白酶D参与了肺纤维化的作用途径与半胱氨酸组织蛋白酶K、S和B不同,肺纤维化加速了Cat D蛋白肽链的断裂,在特发性肺纤维化中主要以成熟的重链形式(-33KDa)参与；莪术油能减少Cat D(～48KDa)中间体向成熟形式发展而抗纤维化。
5莪术油能抑制A549细胞增殖,主要通过阻滞细胞于S期,减少进入分裂期的细胞比例；80 mg.mL-1的莪术油主要通过加速细胞衰老而上调Cat D的表达。
Pulmonary fibrosis(PF) is a kind of diffuse interstitial lung disease which caused by many causes and has similar pathogenesis, Its pathogenic characterize is which alveolar structure destruction and diffuse alveolitise in the early, then cause over aggradation of extracellular matrix(ECM) and gaudily leading to fibrosis, consequently cause respiratory function destruction. Most of the patients died from respiratory failure from progressive pulmonary fibrosis. In clinic idiopathic pulmonary fibrosis(IPF) is the most common. IPF is a kind of pulmonary fibrosis, however, the mechanisma are still unknown. An emerging concept is that the alveolar typeⅡepithelial cells transition into mesenchymal cells via a process termed epithelial-mesenchymal transition(EMT). As pollution, environmental degradation, and so the number of seizures have increased trend every year. The laboratory studies of chinese medicine in the control organs fibrosis found that Zedoary Oil has the effect of remedying pulmonary fibrosis pharmacology. Zedoary Oil is an effective part in Zedoary. Studies show that Zedoary Oil can inhibit the donor cell proliferation, promote the donor cell apoptosis. But the control mechanisms of cellular and molecular about Zedoary Oil are not clear yet. To evaluate the effect of the pathogenesis and role of pulmonary fibrosis induced by Zedoary Oil. Mice model induced by Bleomycin(BLM) and alveolar epithelial cellⅡ(A549)as a model, and describes the effect of Zedoary Oil proliferation, and to discuss the potential mechanism of the inhibiting effect of Zedoary Oil pulmonary fibrosis.
Methods & Results
1 The chemical constituents and yield of the Zedoary Oil
1.1 Method The chemical componentswere of Zedoary Oil are separated and identified by GC/MS. Taking Nist98 standard mass spectrometer database and contrast as control, the structure of themass spectrogram was identified, and relatively reserved time and peak area percentage occupy the peak total area percentage.
1.2 Results 23 compositions were identified from Zedoary Oil. Three single peaked area are larger than ten percentage of the peak total area. Three single peaked area are one out of five or ten of the peak total area,β-Elemene and Curcumol can inhibit the tumor cells growth in the 23 compositions.
2 To study medicine of the Zedoary Oil
2.1 Methods①96 IR mice was divided into four groups:modle group (BLM), medium dose group(Oil M), the high dose group(Oil H) and sham operation group (Sham). A single dose of 0.05 U bleomycin in 100μL of saline'solution was administered by transtracheal puncture. Oil M and Oil H reeeived the same amount of bleomycin as BLM, followed by different amouts Zedoary oil. Sham received normal saline'solution by tratracheally. These mice were killed on 7,14,28 day post bleomycin.The lung tissues were obtained.②Apply the HE staining to investigate the lung inflammation and lung fibrosis under the routine mieroseope.③Use the immunohistochemistry staining and western blotting to study the expression of collagenⅠ、collagenⅢ、TGF-β1、Smad3、Cat B、Cat D and Cat K. Use image analysis software to measure the density.④Use the real time PCR to measure the expression of Cat B. Cat D、Cat K and Cat S.⑤The lung hydroxyproline content was analyzed using a enzymes response method in minced lung.
2.2 Results HE staining display that the alveolar structure of sham is complete and clear. There were no inflammatory cells in alveolus. pulmonary fibrosis were obviously in sham. Consolidation area appeared around bronchus:abnormal thickening of alveolar walls, architectural distortion of alveolar, exudation in alveolus. As time went on, pulmonary fibrosis become serious. thickening and Exudation were seen in sham group that didn't exist in rest group.
Mallory staining results:the collagen layer of tissue section of lung of mice were thin around bronchus. There were the change visible in alveolus.Collagen fibers and deposition of BLM group increased considerably in interstitial lung, alveolar, bronchus, vessels.Blue fabric of BLM group increased obviously in alveolus interval.The changes of two treatment groups is lower than BLM group.
Immunohistochemistry(IHC) staining results:normal structure of alveolar was destroyed by the deposition of I type collagen as fibrosis went on. The changes of two treatment groups is lower than BLM group.Ⅲtype collagen primarily on the vessels and bronchi. The collagen increased day by day and reached the highest at 7th day. deposition ofⅢtype collagen on the lung break down along with times.The expression ofⅢtype collagen approximate the normal level at 28th day.Compare to sham grounp, the content ofⅢtype collagen increassd day by day and reached the highest at 7th day, second at 14th day.The content get less at 28th day. two treatment groups can reduce the deposition of III type collagen on the lung.
EMT of signal elements and Cathepisins of IHC staining results:EMT were urging TGF-β1 activated. The expression ofα-SMA in alveolar increased, and so the expression of Smad3. activated Cat K、Cat B and Cat S can promote degradation of collagen. Activated Cat D is correlated with pulmonary fibrosis. Compare to sham grounp, the expression of singnal in EMT decreased. the expression of Cat K、Cat B and Cat S increased. Cat D was inhibited.
3 The pharmacologic mechanism of proliferation of A549 cell by the Zedoary Oil
3.1 Methods The experiment measures that the effect on the regeneration of cell, the regulation of cell, the apoptosis of cell, the deposition of collagen and up cathepsins expression when the Zedoary Oil act on open educational A549 cell.
3.2 Results when the concentration of the Zedoary Oil is 80 mg·mL-1, cell cycle was arrested at S stage. At the same time, some cell was apoptosis or necrosis. the expression of Cat D and Cat K increased.
Conclusion
1 The chemical componentswere separated and identified by GC/MS.23 compositions were identified from Zedoary Oil,β-Elemene and Curcumol which can inhibit the tumor cells growth.
2 The Zedoary Oil can promote the gas eschange and the survival rate through maintaining the normal structure of alveolar. The exhibition of basis of cell give priority to the deposition of I type collagen.at the same time, the deposition of III type collagen increased.
3 The Zedoary Oil can prevent the formation of Pulmonary fibrosis through inhibiting EMT in the modle of Pulmonary fibrosis which induced by BLM.
4 The Zedoary Oil can prevent the formation of Pulmonary fibrosis throug hinhibiting some immunocompetence of TGF-β1, increasing the expression of Cat K、Cat S and Cat B mRNA and reducing the deposition of EMT. Cat D different from Cat K、Cat S and Cat B,
5 The Zedoary Oil can inhibit the regeneration of cell through arresetting cell cycle at S stage and reducing the rate of cell division.80 mg·mL-1 can increase the expression of Cat D though accelerating cell senescence.
肺纤维化是指由多种病因引起的具有相似病理过程的一类弥漫性肺间质疾病,常发生在肺泡,早期有肺泡结构破坏和弥漫性肺泡炎,继后出现细胞外基质过度沉积,并逐渐演变为弥漫性肺间质纤维化,是肺脏损伤的结果。病人多死于进行性加重的肺纤维化所致的呼吸衰竭。在临床上又以特发性肺纤维化(IPF)最为常见。随着污染、环境恶化及药物等因素的影响,发病人数有逐年增加的趋势,但其作用机制尚不清楚,肺泡上皮细胞发生了上皮细胞间质转化可能是肺纤维化的机制之一。本实验室在前期研究中医药防治器官纤维化中发现莪术具有抗肺纤维化的药理活性。莪术油是莪术中有效提取部位,研究表明其能抑制体外培养细胞的增殖和凋亡。但是莪术油抗肺纤维化的细胞和分子调控机理目前还不清楚。为阐明莪术油对IPF的作用及可能的作用机制,本研究以博来霉素诱导的特发性肺纤维化小鼠和人肺Ⅱ型上皮细胞A549为模型,研究莪术油对特发性肺纤维化小鼠和A549细胞增殖的作用,并初步探讨了其抑制肺纤维化的机制。
研究方法及结果
1药物中成份鉴定及含量测定
1.1方法本实验以莪术油为研究对象,利用气相色谱-质谱联用技术(GC-MS)对其化学成份进行分析。莪术油样品在GC-MS仪进样后,利用Nist98标准质谱图库及相关标准品进行对照,鉴定其结构,所得结果以相对保留时间和峰面积所占百分比表示。
1.2结果共鉴定色谱峰23个,其中单峰面积占总峰面积大于10%的峰有三个单峰面积占总峰面积在5-10%的峰有三个；在23个化合物中有广泛抗肿瘤活性的p-榄香烯和莪术醇。
2整体实验评价莪术油对特发性肺纤维化小鼠的效果及作用机制
2.1方法①IR小鼠96只,随机分为4组：模型组(BLM)、莪术油中剂量组(OilM)、莪术油高剂量组(Oil H)及假手术组(Sham).模型组(BLM)、莪术油中剂量组(Oil M)、莪术油高剂量组(Oil H)经气管内注入博莱霉素(0.05 U/只)诱导肺纤维化,随即分别每日腹腔注射生理盐水和不同剂量莪术油(Oil M按100 mg·kg-1剂量给药,Oil H按200 mg·kg-1剂量给药)；假手术组(Sham)以生理盐水代替。各组动物均于气管内灌药后第7、14、28天分别处死8只,取肺组织。②HE染色,光镜下观察各组小鼠肺组织,进行肺泡炎、肺纤维化的分级。③用免疫组化方法和Western blotting检测各组小鼠肺内Ⅰ型胶原、Ⅲ型、TGF-β1、Smad3、Cat B、Cat D和Cat K的表达,并用图像分析软件检测各组的光密度。④实时荧光PCR法检测各组Cat B、Cat D、Cat K和Cat S的表达。⑤酶法检测肺组织匀浆中羟脯氨酸含量。
2.2结果
HE染色显示,假手术组肺泡结构完整、清晰,肺泡腔内无明显渗出物；模型组纤维化程度明显,在支气管周围有大片实变区,肺泡壁异常增厚,肺泡结构紊乱,腔内有渗出物,纤维化程度随时间的进展而加深加重；莪术油各剂量组肺泡结构较为清晰,在支气管周围有局部纤维化,肺泡间隔增厚,较模型组有所减轻。
Mallory染色显示,假手术组小鼠肺肺切片中胶原层在支气管壁周围较薄,肺泡区散在；模型组肺间质、肺泡区、支气管、血管周围胶原纤维明显增多,并向间质沉积,增宽的肺泡间隔蓝色纤维增多尤为明显；两个治疗组的胶原沉积低于模型组。
羟脯氨酸测定结果表明,模型组小鼠肺组织匀浆中的含量明显升高,莪术油高、中剂量组均降低其的含量,以第7天的作用最为明显。
胶原免疫组化结果表明,Ⅰ型胶原主要表达于肺间质,随纤维化的进展加深加重,大量的Ⅰ型胶原在肺泡区沉积,破坏了肺泡的正常结构,两个治疗组肺切片中Ⅰ型胶原的沉积均较模型组的下降。Ⅲ型胶原主要表达于血管和支气管上皮,以第7天时的表达量最高,随时间延长肺组织中沉积的Ⅲ型胶原逐渐减少,到第28天时,Ⅲ型胶原的表达量接近正常水平。与假手术组相比,模型组Ⅲ型胶原的含量均升高,以第7天的表达量最高,14天次之,28天时的含量最低。两个治疗组在一定程度上降低Ⅲ型胶原在肺组织中的沉积。
上皮细胞转分化相关蛋白及组织蛋白酶活性相关检测结果表明,特发性肺纤维化小鼠肺上皮细胞经历了上皮细胞间质转化,TGF-β1显著活化,促使α-SMA在肺泡区表达增强,下游信号分子Smad3表达增强,活化的Cat K、CatB和Cat S促使胶原降解,活化的Cat D加重了肺纤维化。两个治疗组较模型组中信号分子表达减弱,Cat K、Cat B和Cat S信号表达增强,Cat D的活化被抑制。
3莪术油对A549细胞增殖抑制机理
3.1方法本实验通过体外培养A549细胞,莪术油干预后,测定其对细胞增殖、细胞周期、细胞凋亡、胶原沉积及组织蛋白酶活性等方面的影响。
3.2结果莪术油剂量为80 mg·mL-1时,细胞阻滞于S期,并伴随凋亡和坏死事件的发生；Cat D、Cat K的表达均上调。
结论
1使用GC-MS分析技术,对莪术油进行了化学成分研究,分离了23种化学结构,其中包含广泛报道的具有肿瘤抑制活性的p-榄香烯、莪术醇。
2莪术油能改善特发性肺纤维化小鼠炎性细胞浸润,维持肺泡结构正常,以利于肺内气体交换,提高生存率；细胞外基质以Ⅰ型胶原的沉积为主,伴有Ⅲ型胶原的增生。
3博来霉素诱导的肺纤维化模型中,上皮细胞经历了间质转化,莪术油能抑制纤维形成期上皮细胞的间质转化,从而有效的拮抗肺组织纤维化。
4半胱氨酸组织蛋白酶K、S、B参与纤维化小鼠肺组织细胞外基质的重构,但其作用时间受到活化的TGF-β1的抑制而延后；莪术油能部分抑制TGF-β1免疫活性,提高纤维化肺组织中半胱氨酸组织蛋白酶K、S和B mRNA水平,降低大量沉积的细胞外基质而抑制纤维化的发展。组织蛋白酶D参与了肺纤维化的作用途径与半胱氨酸组织蛋白酶K、S和B不同,肺纤维化加速了Cat D蛋白肽链的断裂,在特发性肺纤维化中主要以成熟的重链形式(-33KDa)参与；莪术油能减少Cat D(～48KDa)中间体向成熟形式发展而抗纤维化。
5莪术油能抑制A549细胞增殖,主要通过阻滞细胞于S期,减少进入分裂期的细胞比例；80 mg.mL-1的莪术油主要通过加速细胞衰老而上调Cat D的表达。
Pulmonary fibrosis(PF) is a kind of diffuse interstitial lung disease which caused by many causes and has similar pathogenesis, Its pathogenic characterize is which alveolar structure destruction and diffuse alveolitise in the early, then cause over aggradation of extracellular matrix(ECM) and gaudily leading to fibrosis, consequently cause respiratory function destruction. Most of the patients died from respiratory failure from progressive pulmonary fibrosis. In clinic idiopathic pulmonary fibrosis(IPF) is the most common. IPF is a kind of pulmonary fibrosis, however, the mechanisma are still unknown. An emerging concept is that the alveolar typeⅡepithelial cells transition into mesenchymal cells via a process termed epithelial-mesenchymal transition(EMT). As pollution, environmental degradation, and so the number of seizures have increased trend every year. The laboratory studies of chinese medicine in the control organs fibrosis found that Zedoary Oil has the effect of remedying pulmonary fibrosis pharmacology. Zedoary Oil is an effective part in Zedoary. Studies show that Zedoary Oil can inhibit the donor cell proliferation, promote the donor cell apoptosis. But the control mechanisms of cellular and molecular about Zedoary Oil are not clear yet. To evaluate the effect of the pathogenesis and role of pulmonary fibrosis induced by Zedoary Oil. Mice model induced by Bleomycin(BLM) and alveolar epithelial cellⅡ(A549)as a model, and describes the effect of Zedoary Oil proliferation, and to discuss the potential mechanism of the inhibiting effect of Zedoary Oil pulmonary fibrosis.
Methods & Results
1 The chemical constituents and yield of the Zedoary Oil
1.1 Method The chemical componentswere of Zedoary Oil are separated and identified by GC/MS. Taking Nist98 standard mass spectrometer database and contrast as control, the structure of themass spectrogram was identified, and relatively reserved time and peak area percentage occupy the peak total area percentage.
1.2 Results 23 compositions were identified from Zedoary Oil. Three single peaked area are larger than ten percentage of the peak total area. Three single peaked area are one out of five or ten of the peak total area,β-Elemene and Curcumol can inhibit the tumor cells growth in the 23 compositions.
2 To study medicine of the Zedoary Oil
2.1 Methods①96 IR mice was divided into four groups:modle group (BLM), medium dose group(Oil M), the high dose group(Oil H) and sham operation group (Sham). A single dose of 0.05 U bleomycin in 100μL of saline'solution was administered by transtracheal puncture. Oil M and Oil H reeeived the same amount of bleomycin as BLM, followed by different amouts Zedoary oil. Sham received normal saline'solution by tratracheally. These mice were killed on 7,14,28 day post bleomycin.The lung tissues were obtained.②Apply the HE staining to investigate the lung inflammation and lung fibrosis under the routine mieroseope.③Use the immunohistochemistry staining and western blotting to study the expression of collagenⅠ、collagenⅢ、TGF-β1、Smad3、Cat B、Cat D and Cat K. Use image analysis software to measure the density.④Use the real time PCR to measure the expression of Cat B. Cat D、Cat K and Cat S.⑤The lung hydroxyproline content was analyzed using a enzymes response method in minced lung.
2.2 Results HE staining display that the alveolar structure of sham is complete and clear. There were no inflammatory cells in alveolus. pulmonary fibrosis were obviously in sham. Consolidation area appeared around bronchus:abnormal thickening of alveolar walls, architectural distortion of alveolar, exudation in alveolus. As time went on, pulmonary fibrosis become serious. thickening and Exudation were seen in sham group that didn't exist in rest group.
Mallory staining results:the collagen layer of tissue section of lung of mice were thin around bronchus. There were the change visible in alveolus.Collagen fibers and deposition of BLM group increased considerably in interstitial lung, alveolar, bronchus, vessels.Blue fabric of BLM group increased obviously in alveolus interval.The changes of two treatment groups is lower than BLM group.
Immunohistochemistry(IHC) staining results:normal structure of alveolar was destroyed by the deposition of I type collagen as fibrosis went on. The changes of two treatment groups is lower than BLM group.Ⅲtype collagen primarily on the vessels and bronchi. The collagen increased day by day and reached the highest at 7th day. deposition ofⅢtype collagen on the lung break down along with times.The expression ofⅢtype collagen approximate the normal level at 28th day.Compare to sham grounp, the content ofⅢtype collagen increassd day by day and reached the highest at 7th day, second at 14th day.The content get less at 28th day. two treatment groups can reduce the deposition of III type collagen on the lung.
EMT of signal elements and Cathepisins of IHC staining results:EMT were urging TGF-β1 activated. The expression ofα-SMA in alveolar increased, and so the expression of Smad3. activated Cat K、Cat B and Cat S can promote degradation of collagen. Activated Cat D is correlated with pulmonary fibrosis. Compare to sham grounp, the expression of singnal in EMT decreased. the expression of Cat K、Cat B and Cat S increased. Cat D was inhibited.
3 The pharmacologic mechanism of proliferation of A549 cell by the Zedoary Oil
3.1 Methods The experiment measures that the effect on the regeneration of cell, the regulation of cell, the apoptosis of cell, the deposition of collagen and up cathepsins expression when the Zedoary Oil act on open educational A549 cell.
3.2 Results when the concentration of the Zedoary Oil is 80 mg·mL-1, cell cycle was arrested at S stage. At the same time, some cell was apoptosis or necrosis. the expression of Cat D and Cat K increased.
Conclusion
1 The chemical componentswere separated and identified by GC/MS.23 compositions were identified from Zedoary Oil,β-Elemene and Curcumol which can inhibit the tumor cells growth.
2 The Zedoary Oil can promote the gas eschange and the survival rate through maintaining the normal structure of alveolar. The exhibition of basis of cell give priority to the deposition of I type collagen.at the same time, the deposition of III type collagen increased.
3 The Zedoary Oil can prevent the formation of Pulmonary fibrosis through inhibiting EMT in the modle of Pulmonary fibrosis which induced by BLM.
4 The Zedoary Oil can prevent the formation of Pulmonary fibrosis throug hinhibiting some immunocompetence of TGF-β1, increasing the expression of Cat K、Cat S and Cat B mRNA and reducing the deposition of EMT. Cat D different from Cat K、Cat S and Cat B,
5 The Zedoary Oil can inhibit the regeneration of cell through arresetting cell cycle at S stage and reducing the rate of cell division.80 mg·mL-1 can increase the expression of Cat D though accelerating cell senescence.
引文
[1]Dempsey,K.M. Kerr,L. Gomersall,et al. Idiopathic pulmonary fibrosis:an update[J].Q J Med,2006,99:643-654.
[2]肖峰,高洁.特发行肺纤维化的治疗进展[J].临床肺科杂志,2007,2(12)：155.
[3]李辉,代媛媛,李国勤.重温肺痿肺痹文献,探讨特发性肺间质纤维化治疗[J].北京中医药,2010,29(11)：839-842.
[4]丁明桥,许朝霞,王鹏.肺间质纤维化的中医发病机制探讨[J].辽宁中医杂志,2009,36(8)：1291-1292.
[5]张燕萍,林琳,王书臣.肺纤通及其拆方对肺间质纤维化模型大鼠Th1/Th2细胞因子的影响[J].江苏中医药,2008,40(7)：78-80.
[6]陈玉柱.尘肺病的辨证论治[J].中医杂志(增刊),2009,50(12)：77-78.
[7]李柏颖.清热解毒澄其源—宋康教授治疗特发性肺纤维化经验介绍[J].浙江中西医结合杂志,2008,18(6)：359-360.
[8]门炜,贾英杰.贾英杰教授辨证治疗放射性肺炎经验[J].现代中西医结合杂志,19(15)：1889-1890.
[9]胡静,郭永洁,刘旭凌,等.凉血活血法对肺纤维化小鼠羟脯氨酸和TGF-β1含量的影响[J].中国中医药信息杂志,2009,16(9)：25-27.
[10]李宇航,黄颖,郭明章,等.清热解毒药物配伍桔梗对COPD大鼠模型病理形态的影响[J].北京中医药大学学报,2008,31(12)：819-822.
[11]郑丰杰,李宇航,王庆国,等.清热解毒药配伍桔梗汤对急性肺损伤大鼠肺核因子Kappa B p65蛋白表达的影响[J].中华中医药杂志(原中国医药学报),2008,23(7)：586-589.
[12]郑丰杰,李宇航,王庆国,等.清热解毒药配伍桔梗汤对急性肺损伤模型大鼠TLR4 mRNA表达的影响[J].北京中医药大学学报,2009,32(9)：594-597.
[13]郑丰杰,李宇航,王庆国,等.清热解毒药配伍桔梗汤对急性肺损伤模型治疗作用的实验观察[J].中华中医药学刊,2008,26(5)：944-946.
[14]杨惠琴,李风森.试论益气活血法治疗肺间质纤维化[J].新疆医科大学学报,2008,31(6)：737.
[15]刘玉庆,刘贵颖,吕英等.肺纤维化的中医治疗探讨[J].中医研究,2006,19(12)：1-2.
[16]翟华强,杨毅,姜楠.益气活血法对肺纤维化大鼠胶原动态变化影响[J].中国公共卫生,2008,24(7)：892-893.
[17]刘秀芳,王炳胜,李凤玉,等.益气活血中药对放射损伤大鼠肺组织TGF-β1和Ⅰ、Ⅲ型胶原合成的影响[J].现代肿瘤医学,2010,18(8)：1477-1480.
[18]赵兰才,何福金,董小霞,等.三参保肺颗粒对慢阻肺合并肺纤维化大鼠肺组织Ⅰ、Ⅲ型胶原及转化生长因子β1表达的影响[J].世界中西医结合杂志,2010,5(4)：305-326.
[19]孙增涛,廉富,魏葆琳.益气活血散结法治疗特发性肺纤维化临床与实验研究[J].辽宁中医杂志,2007,34(7)：865-867.
[20]李辉,李国勤,高荣林,等.益气活血通络法治疗特发性肺间质纤维化气虚血瘀证疗效观察[J].中国中医急症,2008,17(10)：1341-1343.
[21]李辉,李国勤,刘俊玲,等.益气活血通络汤治疗肺间质纤维化临床观察[J].中国中医药信息杂志,2009,16(2)：65-66.
[22]潘芳,王洪.益气破血方治疗气虚血瘀型特发性肺间质纤维化的临床观察[J].北京中医药,2010,29(8)：614-616.
[23]胡超群.益气祛瘀化痰汤对特发性肺纤维化患者健康相关生存质量的影响[J].中医学报,2010,25(147)：288-289.
[24]周继朴,苑惠清.益气活血化痰解毒中药静点与口服联用治疗特发性肺间质纤维化急性期的临床研究[J].中华中医药学刊,2008,26(9)：2074-2076.
[25]谭善忠,刘成海,张炜,等.扶正化瘀方对大鼠纤维化肺组织MMP-2活性与Ⅳ型胶原表达的影响[J].中国中药杂志,2007,32(9)：835-839.
[26]陆雄,叶伟成,刘平,等.扶正化瘀方对博莱霉素诱发大鼠肺间质纤维化的干预作用[J].中医杂志,2006,47(7)：538-540.
[27]杨珂,谭善忠,张炜,等.扶正化瘀方抗肺纤维化的药物配伍作用特点[J].中医杂志,2009,50(8)：732-736.
[28]郑心,张兴彩.间质流膏对特发性肺间质纤维化患者CRP评分的影响[J].山东中医药大学学报,2009,33(6)：497-499.
[29]张燕萍,樊茂蓉,王书臣,等.肺纤平对博莱霉素所致肺纤维化大鼠Ⅰ、Ⅲ型胶原的影响[J].中国中西医结合杂志,2007,27(11)：1013-1015.
[30]谭漪,董滟,董慧君.补虚通络法治疗特发性肺纤维化的临床研究[J].时珍国医 国药,2009,20(3)：713-714.
[31]余维巍,刘晓晴.黄芪对内毒素性急性肺损伤大鼠肝细胞生长因子表达的影响[J].中国中西医结合杂志,2005,12(5)：309.
[32]解珂,陶富盛,房晓云,等.黄芪对急性肺损伤鼠中性粒细胞粘附功能的影响[J].临床麻醉学杂志,2006,22(5)：375.
[33]奚蕾,夏德洪,沈伟生,等.清燥救肺汤加黄芪对放射性肺损伤干预作用及对肿瘤坏死因子-α及内皮素表达影响的研究[J].时珍国医国药,2010,21(2)：339-341.
[34]夏德洪,奚蕾,沈伟生,等.清燥救肺汤加黄芪对放射性肺损伤干预作用及对TGF-β1,IL-1表达的影响[J].中国实验方剂学杂志,2010,16(6)：240-243.
[35]夏德洪,奚蕾,沈伟生,等.黄芪对放射性肺损伤干预作用及对TGF-β1,IL-1表达影响的研究[J].中国中药杂志,2010,35(8)：1079-1081.
[36]彭清,辛建保,苏良平,等.黄芪对肺纤维化大鼠MMP-2和TIMP-1表达的影响[J].华中科技大学学报(医学版),2007,35(1)：35-37.
[37]包海勇,王亚丽,吴国泰,等.当归黄芪醇提物与水提物对实验性大鼠肺纤维化的干预作用[J].中国新药杂志,2010,19(12)：1064-1067.
[38]刘永琦,李金田,李娟,等.黄芪对肺纤维化大鼠血清细胞因子及肺超微结构的影响[J].中国免疫学杂志,2008,24(12)：980-983.
[39]张平,李杰平,于小华,等.黄茂甲戒对实验性肺纤维化大鼠Cathepsin B表达的影响[J].现代生物医学进展,2007,7(6)：860-863.
[40]李亚东博士论文
[41]张亮,韩春姬,李莲姬,等.轮叶党参提取物对酒精性肝损伤的保护作用[J].中国组织工程研究与临床康复,2007,11(29)：5742-5744.
[42]金凤华,胡芳弟,陈相,等.党参不同提取部分活性比较[J].中药材,2009,32(1)：112-114.
[43]许爱霞,张振明,葛斌,等.党参多糖抗衰老作用机制的实验研究[J].中国现代应用药学杂志,2006,23(8)：729-732.
[44]黄丽亚,叶嗣颖.党参注射液上调抗氧化酶表达作用的实验研究[J].中国老年学杂志,2006,26(1)：70-71.
[45]闫彦芳,张壮,韦颖,等.党参总皂苷抗缺氧缺糖再给氧诱导大鼠星形胶质细胞损伤的作用[J].北京中医药大学学报,2006,29(12)：826-829.
[46]柏长青,遆新宇,刘关键,等.党参、黄芪提取物注射液对减轻肺癌患者化疗毒副反应和生存质量影响的研究[J].中国康复医学杂志,200,21(8)：707-709.
[47]柏长青,宋颖芳,王德堂,等.黄芪、党参提取物增强紫杉醇抑制肿瘤血管生成和转移的实验研究[J].细胞与分子免疫学杂志,2008,24(4)：375-377.
[48]李辉,杜志刚,张学华.黄芪党参汤对肺癌术后放、化疗患者外周血bcl-2表达的影响[J].河北中医,2009,31(10)：1453-1455.
[49]黄丽亚,崔显念.党参与首乌等混合注射液上调抗氧化酶表达作用的实验研究[J].时珍国医国药,2006,17(11)：2195-2196.
[50]黄丽亚,叶嗣颖,刘杰书.党参与天麻对氟哌啶醇致老化大鼠抗氧化酶表达作用的比较研究[J].时珍国医国药,2006,17(9)：1687-1688.
[51]慕桂娟.甘草化学成分的研究进展[J].包头医学2005,29(2)：25-27.
[52]杨莉,陈海霞,高文远,等.甘草抗肿瘤活性成分的研究[J].天然产物研究与开发2009,21(3)：438-440.
[53]何燕,丁维俊,邓国忠,等.肺纤维化模型鼠MMP/TIMP基因表达异常及复方甘草酸苷的调控机制研究[J].现代中西医结合杂志,2008,17(30)：4681-468
[54]何燕,丁维俊,邓国忠,等.复方甘草酸苷对肺纤维化模型大鼠Smad家族基因表达的调控作用研究[J].中国药房,2009,20(19)：1454-1456.
[55]吕小华,吴铁,覃冬云.甘草酸对肺纤维化模型大鼠羟脯氨酸、玻璃酸、层粘连蛋白的干预作用[J].中国药房,2008,19(25)：1954-1955.
[56]叶进燕,陈少贤,谢于鹏,等.甘草甜素抑制肺纤维化大鼠肺组织单核细胞趋化蛋白-1的表达[J].中国病理生理杂志,2007,23(5)：1019-1021.
[57]叶进燕,陈少贤,徐红蕾,等.甘草甜素对大鼠肺纤维化的干预作用及对转化生长因子表达的影响[J].中华结核和呼吸杂志,2006,29(9)：636-637.
[58]丁旭春,王新华,王真.复方甘草甜素治疗博莱霉素致肺纤维化大鼠的研究[J].现代中西医结合杂志,2008,17(27)：4237-4239.
[59]王新华,丁旭春,王真.复方甘草甜素对博莱霉素致肺纤维化大鼠的实验研究[J].中华中医药学刊,2008,26(12)：2628-2630.
[60]李江,武芳,黄茂,等.川芎嗪注射液对博莱霉素致肺纤维化大鼠转化生长因子干预作用的研究[J].时珍国医国药,2007,18(6)：1882-1883.
[61]李江,武芳,黄茂,等.川芎嗪对肺纤维化大鼠Ⅲ型胶原及层黏连蛋白的干预作用[J].实用儿科杂志,2007,22(4)：290-291.
[62]李江,武芳,黄茂,等.川芎嗪对博莱霉素致肺纤维化大鼠病理形态学及细胞外基质的干预作用[J].中华中医药杂志,2007,22(9)：613-614.
[63]王浴生,邓文龙,薛春生.中药药理与应用.第2版.人民卫生出版社,1998：895
[64]谭敏,宾晓农,吴万垠等.莪术油对小鼠肝癌细胞原位凋亡的影响[J].中西医结合肝病杂志,2002,12(5)：290-291.
[65]吴万垠,罗云坚,程剑华等.莪术油对小鼠肝癌细胞DNA作用的图像分析[J].中西医结合肝病杂志,1999,9(1)：18.
[66]Zhu Qingjing,Xiong Zhenfang,Yang Lin. Effects of β-elemene on the expression of Bcl-2 family in hepatic stellate cells[J]. Chin J Integr Trad West Med Dig,2007,15(3):151-155.
[67]Tang Yuan,Li Xiaohui,Inhibitory efects of Zedoray Rhizome abstracts on hepatic cell line HepG2 and their mechanisms. Chinese Pharmacological Bulletin 2007,23(6):790-794.
[68]Fang Ning,Chen Daixiong,Wan Haiyan. Early apoptosls of mice hepatoma HcaF cells induced by β-elemel[J]. Gui Zhou Medleal Journal.2001,25(12):1061-1062.
[69]张维彬,谭敏,肖刚等.莪术油诱导小鼠HepA肝癌细胞凋亡及其对bcl-2蛋白表达的影响.现代中西医结合杂志,2009,18(4)：370-371.
[70]王娟,王顺启,倪虹等.莪术挥发油抑制人肝癌细胞株SMMC-7721生长的实验研究.天津中医药,2003,20(1)：48-50.
[71]吴万垠,郭伟剑,常钢.莪术油微球释放莪术油对人肝癌SM MC-7721细胞的作用.世界华人消化杂志,2003,11(3)：260-263.
[72]Jiang Yuan,Li Zesong,Jiang Fusheng,et al. Influence of curcumol on gene expression of cultured HSC-T6 cells with DNA microarray[J]. Chin J Integr Trad West Med Dig,2005,13(3):144-147.
[73]宋利琼,张昌菊.莪术油联合干扰素对小鼠宫颈癌端粒酶活性和细胞凋亡的影响.上海中医药杂志,2006,40(7)：68-69.
[74]Chen Guang,Ding Xiaofei,Xiao Jinfang,et al. Experimental studies on apoptosis induced by B-elemene derivate in HeLa cells[J]. Chinese Pharmacological Bulletin,2007,23(2):246-250.
[75]刘明远,张春斌,候霞等.榄香烯诱导人卵巢癌细胞COC1细胞凋亡的研究[J].中国临床医芮研究杂志,2003,98：9933-9934.
[76]李传伟,徐英萍,苗芳等.莪术油抗小鼠结肠癌效应的实验研究.泰山医学院学报,2005,26(2)：89-91.
[77]Huang Fuchun,Fan Yu,Zheng Shu. Efect of Elemene on the Telomerase Activity Apoptosis and Cell Cycles of the Colon Can cer Lovo Cell Line[J]. Herald of Medicine,2004,23(10):712-714.
[78]Huang Fuchun,Fan Yu,Lin Gengjin,et al. Fudan Univ J Med Sc,2003,30(1):49-51.
[79]吴冬梅,杨荣宁.莪术油对鼻咽癌CNE-2细胞的凋亡及放疗增敏机制的影响[J].肿瘤防治研究,2008,25(11)：778-781.
[80]刘跃明,孙立群,王义.榄香烯诱导Hep-2细胞凋亡及其对细胞周期各时相的影响[J].中国老年学杂志,2008,28(5)：868-869.
[81]Xu Lichun,Bu Ping,Xu Xiangyu. Experimental Therapeutic Effect of Tumor Cell Vaccine Constructed by Curcumol on Gastric Cancer[J]. Journal of Traditional Chinese Medicine,2007,48(5):450-452.
[82]高鹏,徐立春,陈平等.莪术醇生物构建自体瘤苗治疗晚期胃癌患者近期疗效研究[J].吉林中医药,2008,28(1)：54-58.
[83]徐立春,卜平,陈平等.莪术醇瘤苗生物治疗胃肿瘤13例[J].肿瘤学杂志,2007,13(4)：303-304.
[84]Lu Xian,Xiang Jinfeng. The influence ofβ-elemene on cell cycle and apoptosis of K562 Cells and the investigation of its mechanism[J]. J China Pediatr Blood Cancer,2008,13(4):148-151.
[85]吉庆明.榄香烯对白血病K562细胞中凋亡相关基因PDCD5表达的影响[J]. 中国医药指南,2008,6(3)：16-18
[86]Perl M,Chung CS,Ayala A.Apoptosis[J].Crit Care Med,2005,33:S526-S529.
[87]赵娜,郭治昕,赵雪,等.丹参的化学成分与药理作用[J].国外医药·植物药分册,2007,22(4)：155-160.
[88]赵宗江,刘昆,张迎雪,等.异病同治和同病异治理论在多器官纤维化中的运用[J].中医杂志,2005,46(10)：727-729.
[89]董静,罗桂林,苗维纳,等.丹参对实验性肺纤维化小鼠病理变化和核因子KB表达的影响[J].中国药理学通报,2003,19(12)：1428-1431.
[90]莫晓能,陈文彬.丹参防治肺动脉高压的研究[J].中国中西医结合杂志,1999,19(4)：252-253.
[91]沙莉,郭锡熔,余章斌.丹参对高体积分数氧致新生大鼠支气管肺发育不良的影响[J].实用儿科临床杂志,2008,23(6)：446-448.
[92]施昌礼,李秋根.丹参对矽肺肺纤维化的实验研究[J].中外医疗,2008,14：20-21.
[93]王作刚,甘卉.麦门冬、丹参对肺纤维化大鼠肺组织SOD、MDA、Hyp的影响[J].中国误诊学杂志,2009,9(34)：8347-8348.
[94]林军,冯一中,顾振纶,等.丹参总酚酸对博莱霉素致肺纤维化小鼠的治疗作用[J].中草药,2009,39(3)：400-403.
[95]陆海英,周娟,陆敏,等.丹参酚酸B对实验性肾间质纤维化大鼠的保护作用及其机制[J].中药材,2010,33(11)：1755-1759.
[96]周娟,张悦,陆海英.丹参酚酸B盐对大鼠肾纤维化的影响[J].中国中药杂志,2009,34(21)：2790-2793.
[97]周娟,王飞,陆海英,等.丹参酚酸B盐对TGF-β1诱导的HK-2上皮-间充质转分化的影响[J].中国中药杂志,2010,35(1)：89-93.
[98]李广虎,李志平,徐泳,等.丹参酮ⅡA对放射性肺纤维化防治作用的实验研究[J].中华放射肿瘤学杂志,2006,15(1)：50-54.
[99]孙瑞芳,刘立新,张海燕,等.丹参酮ⅡA对小鼠肝纤维化的干预作用[J].中国中西医结合杂志,2009,29(11)：1012-1017.
[100]李醇文,周亚光,陈娣,等.丹参酮ⅡA对自发性高血压大鼠心肌纤维化的影响中华中医药杂志(原中国医药学报),2010,25(12)：2143-2146.
[101]Literat A, Su F, Norwicki M, et al. Regulation of pro-inflammatory cytokine expression by curcumin in hyaline membrane disease(HMD)[J]. Life Sci,2001,70(3):253.
[102]王建军,王三萍,熊海金,等.姜黄素对哮喘大鼠气道炎症与KB表达的影响[J].中国临床康复,2005,9(11)：102.
[103]姜黄素对哮喘大鼠气道胶原沉积及转化生长因子p1表达的影响[J].临床儿科杂志,2005,23(9)：659-661.
[104]解克芳,牛建昭,王继峰,等.姜黄素对人胚肺成纤维细胞的生长抑制及细胞外基质合成的影响[J].医学研究生学报,2008,21(4)：339-342.
[1]F. BU hling,N. Waldburg,A. Reisenauer,et al. Lysosomal cysteine proteases in the lung:role in protein processing and immunoregulation[J]. Eur Respir J 2004; 23: 620-628.
[2]Gilles Lalmanach,Rlisabeth Diot,Emmanuel Godat,et al. Cysteine cathepsins and caspases in silicosis[J].Biol. Chem.,2006,387:863-870.
[3]Ebisui C,Tsujinaka T,Morimoto T,et al. Interleukin-6 induces proteolysis by activating intracellular proteases (cathepsins B and L,proteasome) in C2C12 myotubes. Clin Sci 1995; 89:431-439.
[4]Li Q,Bever CTJ. Gamma interferon induced increases in intracellular cathepsin B activity in PMA primed THP-1 cells are blocked by inhibitors of protein kinase C. Immunopharmacol Immunotoxicol 1996; 18:375-396.
[5]Ling H,Vamvakas S,Busch G,et al. Suppressing role of transforming growth factor-b1 on cathepsin activity in cultured kidney tubule cells. Am J Physiol 1995; 269:F911-F917.
[6]Lugering N,Kucharzik T,Stein H,et al. IL-10 synergizes with IL-4 and IL-13 in inhibiting lysosomal enzyme secretion by human monocytes and lamina propria mononuclear cells from patients with inflammatory bowel disease. Dig Dis Sci 1998; 43:706-714.
[7]Watari M,Watari H,Nachamkin I,Strauss JF. Lipopolysaccharide induces expression of genes encoding proinflammatory cytokines and the elastin degrading enzyme,cathepsin S,in human cervical smooth-muscle cells. J Soc Gynecol Investig 2000; 7:190-198.
[8]Li Q,Falkler WAJ,Bever CTJ. Endotoxin induces increased intracellular cathepsin B activity in THP-1 cells. Immunopharmacol Immunotoxicol 1997; 19:215-237.
[9]Billington CJ,Mason P,Magny MC,Mort JS. The slowbinding inhibition of cathepsin K by its propeptide. Biochem Biophys Res Commun 2000; 276:924-929.
[10]Bromme D,Li ZQ, Barnes M,Mehler E. Human cathepsin V functional expression,tissue distribution,electrostatic surface potential,enzymatic characterization,and chromosomal localization. Biochemistry 1999; 38:2377-2385.
[11]Lennon-Dumenil AM,Roberts RA,Valentijn K,et al. The p41 isoform of invariant chain is a chaperone for cathepsin L. EMBO J 2001; 20:4055-4064.
[12]Ni J,Fernandez MA,Danielsson L,et al. Cystatin F is a glycosylated human low molecular weight cysteine proteinase inhibitor. J Biol Chem 1998; 273:4797-24804.
[13]Lennon-Dumenil AM,Bakker AH,Maehr R,et al. Analysis of protease activity in live antigen-presenting cells shows regulation of the phagosomal proteolytic contents during dendritic cell activation. J Exp Med 2002; 196:529-540.
[14]Schick C,Bro¨mme D,Bartuski AJ,Uemura Y,Schechter NM,Silverman GA. The reactive site loop of the serpin SCCA1 is essential for cysteine proteinase inhibition. Proc Natl Acad Sci USA 1998; 95:13465-13470.
[15]Levicar N,Strojnik T,Kos J,Dewey RA,Pilkington GJ,Lah TT. Lysosomal enzymes,cathepsins in brain tumour invasion. J Neurooncol 2002; 58:21-32.
[16]程谦,赵久阳.激肽系统与糖尿病肾病关系研究进展[J].国外医学泌尿系统分册,2005,25(4)：569-571.
[17]Mio,T.,Liu,X.,Toews,M. L.,Adachi,et al. Bradykinin augments fibroblast-mediated contraction of released collagen gels. Am. J. Physiol. Lung Cell Mol. Physiol.,2001;281,L164-L171.
[18]Puzer,L.,Vercesi,J.,Alves,M. F.,Barros,N. M.,Araujo,M. S.,Aparecida Juliano,M.,et al. A possible alternative mechanism of kinin generation in vivo by cathepsin L. Biol. Chem.,2005,386,699-704.
[19]Florian Veillard,Fabien Lecaille,Gilles Lalmanach. Lung cysteine cathepsins: Intruders or unorthodox contributors to the kallikrein-kinin system?[J] The International Journal of Biochemistry & Cell Biology,2008; 40:1079-1094.
[20]罗敏琪,林妙霞,曹宝华,等.肝病患者血清胱抑素C与肝纤维化的关系[J].中国自然医学杂志,2010,12(4)：260-262.
[21]Cheng XW,Kuzuya M,Nakamura K,et al. Localization of cysteine protease,cathepsin S,to the surface of vascular smooth muscle cells by association with integrin alphanubeta3[J].Am JPathol,2006,168(2):685-694.
[22]Shi GP,Sukhova GK,Grubb A,Ducharme A,Rhode LH,Lee RT,Ridker PM,Libby P,Chapman HA. Cystatin C deficiency in human atherosclerosis and aortic aneurysms. J Clin Invest.1999; 104:1191-1197.
[23]Satu Helske,Suvi Syvaranta,Ken A. Lindstedt,ea al. Increased Expression of Elastolytic Cathepsins S,K,and V and Their Inhibitor Cystatin C in Stenotic Aortic Valves[J]. Arterioscler Thromb Vasc Biol,2006; 26:1791-1798.
[24]Satpal Ahuja,Poonam Ahuja-Jensen,Leif E. Johnson,et al. rd1 Mouse Retina Shows an Imbalance in the Activity of Cysteine Protease Cathepsins and Their Endogenous Inhibitor Cystatin C[J]. Invest. Ophthalmol. Vis. Sci.,2008; 49:1089-1096.
[25]Barrett D G,Catalano J G,Deaton D N,el al. Orally bioavailable sm all molecule ketoamide based inhibitors of cathepsin K [J]. Bioorg Med Chem Lett,2004;14 (10): 254.
[26]王敏,张月琴.以组织蛋白酶K为靶点的新药筛选[J].中国抗生素杂志,2005,30(6)：373-379.
[27]曾广智,谭宁华,贾锐锐等.组织蛋白酶及其抑制剂研究进展[J].云南植物研究[J].2005,27(4)：337-354
[28]贾锐锐,曾广智,谭宁华,等.组织蛋白酶B的新型天然抑制剂[J].云南植物研究2008,30(5)：621-623.
[29]William P. Daley,Sarah B. Peters,Melinda Larsenl. Extracellular matrix dynamics in development and regenerative medicine[J]. Journal of Cell Science,2008,121:255-264.
[30]Frank Buhling,Christoph Rocken,Frank Brasch,et. Pivotal Role of Cathepsin K in Lung Fibrosis[J]. Am J Pathol,2004; 164:2203-2216.
[31]谢德鄂,孙兵,陈季武.半胱氨酸组织蛋白酶与免疫调节[J].生命的化学,2006,26(3)：229-230.
[32]R.Koslowski,K.Knoch,E.Kuhlisch,et. Cathepsins in bleomycin-induced lung injury in rat[J]. Eur Respir J,2003; 22:427-435.
[33]Perl M,Chung CS,Ayala A. Apoptosis.Crit Care Med,33:S526-S529,2005.
[34]French LE,Tschopp J.Protein-based therapeutic approachestargeting death receptors[J]. Cell Death Differ,2003;10:117-123.
[35]Wajant H.Death receptors[J]. Essays Biochem,2003;39:53-71.
[36]MANI CHOPRA,JAYNE S. REUBEN,AVADHESH C. SHARMA Acute Lung Injury:Apoptosis and Signaling Mechanisms [J]. Exp Biol Med,2009;234:361-371.
[37]Peter S. Tang,Marco Mura,Rashmi Seth. Acute lung injury and cell death:how many ways can cells die[J]? Am J Physiol Lung Cell Mol Physiol,2008;294: L632-L641.
[38]Aline Wille,Annegret Gerber,Anke Heimburg,et al. Cathepsin L is involved in cathepsin D processing and regulation of apoptosis in A549 human lung epithelial cells[J]. Biol. Chem.,2004;385:665-670.
[39]Marina Demoz,Roberta Castino,Patrizia Cesaro,et al. Endosomal-Lysosomal Proteolysis Mediates Death Signalling by TNFa,Not by Etoposide,in L929 Fibrosarcoma Cells:Evidence for an Active Role of Cathepsin D[J]. Biol. Chem.,2002;383:1237-1248.
[40]Heide Schmid,Ramona Sauerbrei,Gerold Schwarz,et al. Modulation of the Endosomal and Lysosomal Distribution of Cathepsins B,L and S in Human Monocytes/Macrophages[J]. Biol. Chem.,2002;383:1277-1283.
[41]Ying Wang,Rebecca M. Baron,Guangli Zhu,et al. PU.1 Regulates Cathepsin S Expression in Professional APCs[J]. The Journal of Immunology,2006,176: 275-283.
[42]Faust PL,Kornfeld S,Chirgwin JM. Cloning and sequence analysis of cDNA for human cathepsin D[J].Proc Natl Acad Sci U S A 1985;82:4910-4.
[43]Fujita H,Tanaka Y,Noguchi Y,Kono A,Himeno M,Kato K. Isolation and sequencing of a cDNA clone encoding rat liver lysosomal cathepsin D and the structure of three forms of mature enzymes[J].Biochem Biophys Res Commun 1991;179:190-6.
[44]Godbold GD,Ahn K,Yeyeodu S,Lee LF.Ting JP,Erickson AH. Biosynthesis and intracellular targeting of the lysosomal aspartic proteinase cathepsin D[J].. Adv Exp Med Biol 1998;436:153-62.
[45]Fuse K M,Vetvicka V. Mitogenic function of human pro—cathepsin D:the role of the propeptide[J]. Biochem J,1994; 303:775-780
[46]Glondu M,Liaudet—Coopman E,Derocq D,Platet N,Rochefort H,Garcia M Down—regulation of cathepsin D expression by antisense gene transfer inhibits turn or growth and experimental lung
[47]metastasis of human breast cancer cells. Oncogene 2002;21:5127-5134
[48]Naora H,Montell DJ. Ovarian cancer metastasis:integrating insights from disparate model organisms. Nat Rev Cancer 2005;5:355-366.
[49]Liu Handong,Chen Jian,Zhou Yi,et al.The relationship between the expression of cathepsin D、PCN A and the postoperative recurrence of bening meningiomas[J]. Central China Medical Journal 2006;30:504-505.
[50]Minarowska A,Gacko M,Karwowska A,Minarowski L. Human cathepsin D.Folia Histochem Cytobiol,2008,46(1):23-38.
[51]Warwas M,Taurowska E.Cathepsin D in diagnosis of neoplastic diseases. Postepy Hig Med Dosw,1993,47(4):277-88.
[52]Levicar N,Strojnik T,Kos J,Dewey RA,Plikington GJ,Lah TT. Lysosomal enzymes,cathepsins in brain tumour invasion.J Neuro-Oncol,2002,58:21-32.
[53]Shibata M,Koike M,Waguri S,Zhang G,Koga T,Uchiyama Y. Cathepsin D is specifically inhibited by deoxyribonucleic acids. FEBS Lett.2002,517:281-284.
[54]陈莉萍,杨鹰.组织蛋白酶D mRNA转录和蛋白表达与卵巢癌的关系[J].西南国防医药,2009,19(1)：54-57.
[55]Pardo M,Garcia A,Antrobus R,et al. Biomarker discovcry from uveal melanoma secretomes:identification of gp100 and cathepsin D in patient serum[J]. J Proteome Res,2007,6(7):2802-2811.
[56]Khalkhali EZ,Hendrix MJ. Elucidating the function of secreted maspin: inhibiting cathepsinD-mediated matrix degradation[J]. Cancer Res,2007,67(8): 3535-3539.
[57]Speleman L,Kerrebijn JD,Look MP,et al. Prognostic value of plasmingen activator inhibitor-1 in head and neck squamous cell carcinoma[J]. Head Neck,2007,29(4):341-350.
[58]Deiss LP,Galinka H,Berissi H,Cohen O,. Cathepsin D protease mediates programmed cell death induced by interferon gamma. Eur Mol Biol Org J. 1996,15:3861-3870.
[59]Deiss LP,Galinka H,Berissi H,Cohen O,Kimchi A. Cathepsin D protease mediates programmed cell death induced by interferon gamma,Fas/APO-1 and TNF alpha. EMBO J.1996,15:3861-3870.
[60]Melanie Beaujouin,Emmanuelle Liaudet-Coopman.Cathepsin D overexpressed by cancer cells can enhance apoptosis-dependent chemo-sensitivity independently of its catalytic activity. Adv Exp Med Biol,2008,617:453-461.
[61]Berchem GJ,Glondu M,Gleizes M,Brouillet JP,Garcia M,Liaudet-Coopman E. Cathepsin-D affects multiple steps of tumor progression:proliferation, angiogenesis and apoptosis.Oncogene,2002,51:5951-5955.
[62]Koike M,Shibata M,Ohsawa Y,Nakanishi H,Koga T,kametaka S,Waguri S,Momoi T,Kominami E,Peters Ch,von Figura K,Sftig P,Uchiyama Y. Involvement of two different cell death pathways in retinal atrophy of cathepsin D deficient mice. Moll Cell Neuroscience,2003,22:146-161.
[63]Koslowski R,Knoch K,Wenzel K-W. Proteinases and proteinase inhibitors during the development of pulmonary fibrosis in rat. Clin Chim Acta,1998,271:45-56.
[64]R. Koslowski,K. Knoch,E. Kuhlisch,D. Seidel and M. Kasper.Cathepsins in bleomycin-induced lung injury in rat. Eur Respir J,2003,22:427-435.
[65]Xiaopeng Li,Heather Rayford,Ruijie Shu,Jiaju Zhuang,and Bruce D. Uhal Essential role for cathepsin D in bleomycin-induced apoptosis of alveolar epithelial cells.Am J Physiol Lung Cell Mol Physiol,2004,287:L46-L51.
[66]Inaoka T,Bilbe G,Ishibashi O,et al.Molecular cloning of human cDNA for cathepsin K:Novel cysteine proteinase predominantly expressed in bone.Biochem Biophys Res Commun,1995,206:89-96.
[67]Patil AD,Freyer AJ,Carte B,et al.Haploscleridamine,a novel tryptamine-derived alkaloid from a sponge of the order haplosclerida:an inhibitor of cathepsin k. J Nat Prod,2002,65:628-629.
[68]Lecaille F,Bromme D,Lalmanach G. Biochemical properties and regulation of cathepsin K activity.Biochimie,2008,90:208-226.
[69]Bromme D,Okamoto K,Wang BB,et al.Human cathepsin O2:a matrix protein-degrading cysteine protease expressed in osteoclasts,functional expression of human cathepsin O2 in Spodoptera frugiperda and characterization of the enzyme [J]. J Biol Chem,1996,271 (4):2126-2132.
[70]Garnero P,Borel O,Byrjalsen I,et al.The collagenolytic activity of cathepsin K is unique among mammalian proteinases [J].J Biol Chem,1998,273(48): 32347-32352.
[71]Rieman DJ,Mcclung HA,Dodds RA,et al. Biosynthesis and processing of cathepsin K in cultured human osteoblasts.Bone,2001,28:282-289.
[72]韩峻峰,罗敏Cathepsin K的研究进展[J].国际内分泌代谢杂志,2006,26(2)：125-127.
[73]韩峻峰,尹晓,李晓华,等Cathepsin K在脂肪细胞分化中的表达及作用[J].上海交通大学学报(医学版).2006,126(1)：59-62.
[74]Podgorski I,Linebaugh BE,Sloane BF.Cathepsin K in the bone microenvironment:link between obesity and prostate cancer?. Biochemical Society,2007,35(Pt 4):701-703.
[75]Barb,D.,Pazaitou-Panayiotou,K. and Mantzoros.Adiponectin:a link between obesity and cancer. Expert Opin Investig Drugs.2006,15(8):917-931.
[76]Williams GA,Wang Y,Callon KE,Watson M,Lin JM,el al. In vitro and in vivo effects of adiponectin on bone. Endocrinology,2009,150(8):3603-10.
[77]Sasaki T,Gohring W,Man K. limited cleavage of ext racellular mat rix protein BM240 by mat rix metalloproteinases increases its affinity for collagens. J Biol Chem,1997,272:9237-9243.
[78]尹晓,陈述林,刘志芬,等.肥胖症患者脂肪组织中组织蛋白酶K的表达及其功能初探[J].中国糖尿病杂志,2008,16(5)：265-266.
[79]Lutgens E,Lutgens SP,Faber BC,et al.Disruption of the cathepsin K gene reduces atherosclerosis progression and induces plaque fibrosis but accelerates macrophage foam cell formation [J].Circulation,2006,113(1):98-107.
[80]刘颖娴,李向平.组织蛋白酶 K与心血管疾病[J].中国动脉硬化杂志,2008,16(1)：75-77.
[81]Turk B Targeting proteases:successes,failures and future prospects. Nat. Rev. Drug Discov,2006;5:785-799.
[82]Morko J,Kiviranta R,Mulari MT,Ivaska KK,Vaananen HK,Vuorio E,Laitala-Leinonen T.Overexpression of cathepsin K accelerates the resorption cycle and osteoblast differentiation in vitro. Bone,2009,44(4):717-28.
[83]吴艳,王毅,杨刚毅.组织蛋白酶K与骨质疏松的研究进展[J].中国骨质疏松杂志,2006,12(5)：522-524.
[84]Konttinen YT,Takagi M,Mandelin J,et al. Acid attack and cathepsin K in bone resorption around total hip replacement prosthesis. J. Bone Miner. Res. 2001;16:1780-1786.
[85]Skoumal M,Haberhauer G,Kolarz G,Hawa G,Woloszczuk W,Klingler A. Serum cathepsin K levels of patients with longstanding rheumatoid arthritis:correlation with radiological destruction. Arthritis Res. Ther.2005;7:R65-R70.
[86]Lecaille F,Bromme D,Lalmanach G. Biochemical properties and regulation of cathepsin K activity. Biochimie.2008;90:208-226.
[87]Mrigank Srivastava,Kathrin Steinwede,el al. Overexpression of cathepsin K in mice decreases collagen deposition and lung resistance in response to bleomycin-induced pulmonary fibrosis. Respiratory Research,2008,9:54
[88]Knaapi J,Lukkarinen H,Kiviranta R,Steiner A,Lassus P,Andersson S,Kaapa P.Cathepsin K expression is diminished in infants with bronchopulmonary dysplasia. Acta Paediatr,2006,95(10):1298-300.
[89]刘剑.组织蛋白酶E氨基端催化性残基的确定[J].中国现代医生,2009,47(20)：1-3.
[90]Zaidi N,Hermann C,Herrmann T,et al.Emerging functional roles of cathepsin E[J].Biochem Biophys Res Commun,2008,377(2):327-330.
[1]王婷,李铁福,林绍强,等.莪术醇的分离鉴定及含量测定[J].中华中医药学刊,2008,26(5)：1018-1021.
[2]杜霞,吴琳华,赵红光.气相色谱-质谱联用测定莪术油中p-榄香烯的含量[J].药物分析杂志,2007,27(2)：216-218.
[3]王建,刘雯,张炜,等.广西不同产地莪术中吉马酮的含量比较[J].时珍国医国药,2009,20(5)：1091-1092.
[4]曹玲,万嵘,王玉.反相高效液相色谱法测定莪术油注射液中莪术醇和栊牛儿酮的含量[J].中国生化药物杂志,2007,28(6)：394-396.
[5]李爱群,胡学军,邓远辉,等.温莪术挥发油的成分[J].中草药,2001,32(9)：782-783.
[6]周欣,李章万,王道平等GC-MS法建立温莪术挥发油指纹图谱研究[J].中国中药杂志,2004,29(12)：1138-1142.
[7]万明珠,梁逸曾,赵晨曦,等.温莪术挥发性化学成分分析和指纹图谱研究[J].时珍国医国药,2009,20(10)：2428-2431.
[8]张慧,孙秀燕,郑艳萍RP-HPLC法分离分析温莪术油中6种倍半萜类成分[J].药物分析杂志,2008,28(12)：1993-1997.
[9]史克莉.不同品种莪术挥发油成分GC-MS分析[J].湖北中医学院学报,2009,11(4)：29-32.
[1]Taskar VS,Coultas DB. Is idiopathic pulmonary fibrosis an encironmental disease?[J] Proc Am Thorac Soc 2006;3:293-98.
[2]Moises Selman,Annie Pardo. Role of epithelial cells in idiopathic pulmonary fibrosis[J]. Proc Am Thorac Soc 2006;3:364-72.
[3]Nagao T,Nagai S,Hiramoto Y,et al. Serial evaluation of high-resolution computed tomography findings in patients with idiopathic pulmonary fibrosis in usual interstitial pneumonia. Respiration,2002,69(5):413-19.
[4]Donald N. Cook,David M. Brass,et al. A Matrix for New Ideas in Pulmonary Fibrosis [J]. Am J Respir Cell Mol Biol,2002,27:122-24.
[5]Nicolas Pottier,Cecule Chupin,Virginie Defamie,et al.Relationships beteeen Early Inflammatory Response to Bleomycin and Sensitivity to Lung Fibrosis[J]Am J Respir Crit Care Med,2007,176:1098-1107.
[6]王响英,吴淑燕,李苏安等.实验性大鼠肺纤维化病理形态及超微结构观察[J].苏州大学学报(医学版),2005,25(3)：379
[7]王浴生,邓文龙,薛春生.中药药理与应用.第2版.人民卫生出版社,1998：895.
[8]宋丽琼,张昌菊.莪术油联合干扰素对小鼠宫颈癌端粒酶活性和细胞凋亡的影响[J].上海中医药杂志,2006,40(7)：68-69.
[9]吴冬梅,杨荣宁.莪术油对鼻咽癌CNE-2细胞的凋亡及放疗增敏机制的影响[J].肿瘤防治研究,2008,35(11)：778-肿瘤防治研究.
[10]唐渊,李晓辉.莪术提取物对肝癌细胞系HepG2的抗癌作用及机制研究[J].中国药理学通报,2007,23(6)：790-794.
[11]张维彬,谭敏,肖刚,等.莪术油诱导小鼠HepA肝癌细胞凋亡及其对bcl-2蛋白表达的影响[J].现代中西医结合杂志,2009,18(4)：370-371.
[12]王娟,王顺启,倪虹,等.莪术挥发油抑制人肝癌细胞株SMMC-7721生长的实验研究[J].天津中医药,2003,20(1)：48-51.
[13]孙增涛,廉富,李小娟,等.肺纤维化模型大鼠肺组织中转化生长因子β1及转化生长因子β1mRNA的表达及黄芪莪术合剂的干预效应[J].中国组织工程研究与临床康复,2007,11(14)：2645-2647.
[14]邱颂平,王英豪,杨素芳.破血化瘀药三棱、莪术对肺纤维化大鼠模型肺形态学及羟脯氨酸的影响[J].福建医科大学学报,2007,41(5)：412-414.
[15]陈贤均,赵红刚.盐制杜仲对小鼠生长发育与脏器系数的影响[J].四川中医,2005,23(11)：29-31.
[16]宋文华,张文佳,张金洋,等.纳米二氧化钛对小鼠肺部生化指标的影响研究[J].南开大学学报(自然科学版),2008,41(3)：14-19.
[17]宋文华,白茹,王雯,等.纳米Ti02材料的环境与健康效应初探[J].南开大学学报(自然科学版),2006,39(6)：41-44.
[18]许祖德,张月娥.陈忠年.博莱霉素诱发大鼠肺纤维化时肺内间质细胞的变化[J].上海医科大学学报,1995,22(2)：93-96.
[19]朱际平,朱海青.肺纤维化大鼠模型肺组织病理超微结构观察及定量分析[J].江苏大学学报(医学版),2007,17(2)：124-127.
[20]陶章,李惠萍.不同剂量博莱霉素致小鼠肺纤维化模型的比较[J].中国组织工程研究与临床康复,2009,13(7)：1214-1218.
[21]袁效涵,黄霞,徐立然,等.不同方剂对肺纤维化模型小鼠的比较研究[J].中成药,2009,31(12)：1827-1829.
[22]Lai CK,Wallace WD,Fishbein MC.Histopathology of pulmonary fibrotic disorders [J].Semin Respir Crit Care Med,2006,27 (6):613-622.
[23]GHOSH A K. Factors involved in the regulation of type I collagen gene9 expression:implication in fibrosis[J]. Exp BiolMed,2002,227(5):301-314.
[24]马跃文,佟振月,侯显明.肺纤维化过程中不同种类胶原异常沉积及分布规律的实验研究[J].中国医科大学学报,2009,38(6)：407-409.
[25]Kim KK,Kugler MC,Wolters PJ,et al.Alveolar epithelial cell mesenchymal transition develops in vivo during pulmonary fibrosis and is regulated by the extracellular matrix [J].Proc Natl Acad Sci USA,2006,103 (35):13180-13185.
[26]Razzaque MS,Hossain MA,Kohno S,et al. Bleomycin-induced pulmonary fibrosis in rat is associated with increased expression of collagen-binding heat shock protein (HSP) 47. Virchows Arch,1998,432(5):455-60.
[27]Endo M,Oyadomari S,Terasaki Y,et al. Induction of arginase Ⅰ and Ⅱ in bleomycin-induced fibrosis of mouse lung. Am J Physiol Lung Cell Mol Physiol, 2003,285(2):L313-21.
[28]Zhang-Hoover J,Sutton A,Stein-Streilein J. CD40/CD40 ligand interactions are critical for elicitation of autoimmune-mediated fibrosis in the lung. J Immunol, 2001,166(5):3556-63.
[29]Nagase T,Uozumi N,Ishii S,et al. A pivotal role of cytosolic phospholipase A(2) in bleomycin-induced pulmonary fibrosis. Nat Med,2002,8(5):480-84.
[30]Hamaguchi Y,Nishizawa Y,Yasui M,et al. Intercellular adhesion molecule-1 and L-selectin regulate bleomycin-induced lung fibrosis. Am J Pathol,2002, 161(5):1607-18.
[31]Van Hoozen BE,Grimmer KL,Marelich GP,et al. Early phase collagen synthesis in lungs of rats exposed to bleomycin. Toxicology,2000,147 (1):1-13.
[1]Kalluri R,Neilson EG. Epithelial-mesenchymal transition and its implications for fibrosis[J]. J Clin Invest,2003,112:1776-1784.
[2]Li Y,Yang J,Dai C,et al. Role for integrin-linked kinase in mediating tubul arepithelial to mesenchymal transition and renal interstitial fibrogenesis[J]. J C lin Invest,2003,112:503-516.
[3]Zavadil J,Bottinger EP. TGF-βand epithelial-to-mesenchymal transitions[J]. Onco Gene,2005,24:5764-5774.
[4]Cheng S,Lovett DH. Gelatinase A (MMP-2) is necessary and sufficient for renal tubular cell epithelial-mesenchymal transformation[J]. Am J Pathol,2003,162: 1937-1949.
[5]Dennler S,Goumans MJ,ten Dijke P. Transforming growth factor-(3signal transduction[J]. J Leukoc Biol,2002,71:731-740.
[6]Sime PJ,O'Reilly KMA. Fibrosis of the lung and other tissues:new concepts in pathogenesis and treatment[J]. Clin Immunol,2001,99:308-319.
[7]Lee JM,Dedhar S,KalluriR,et al. The epithelial-mesenchymal transition:new insights in signaling,development,and disease[J]. J Cell Biol,2006,172(7):973-981.
[8]Zhao J,Shi W,Wang YL,et al. Smad3 deficiency attenuates bleomycin-induced pulmonary fibrosis in mice[J]. Am J Physiol Lung Cell Mol Physiol,2002,282: L585-L593.
[9]Nawshad A,Lagamba D,Polad A,et al. Transforming growth factor-beta signaling during epithelial-mesenchymal transformation:implications for embryogenesis and tumor metastasis[J]. Cells Tissues Organs 2005,179:11-23,
[10]Nawshad A,Lagamba D,Polad A,et al. Transforming growth factor-beta signaling during epithelial-mesenchymal transformation:implications for embryogenesis and tumor metastasis[J]. Cells Tissues Organs,2005,179:11-23.
[11]Thiery JP. Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer,2002,2:442-454.
[12]Kasai H,Allen JT,Mason RM,et al. TGF-1 induces human alveolar epithelial to mesenchymal cell transition (EMT)[J]. Respir Res,2005,6:56.
[13]Willis BC,Liebler JM,Luby-Phelps K,et al. Induction of epithelial-mesenchymal transition in alveolar epithelial cells by transforming growth factor-betal:potential role in idiopathic pulmonary fibrosis[J]. Am J Pathol,2005,166:1321-1332.
[14]Flanders KC. Smad3 as a mediator of the fibrotic response. Int J Exp Pathol,2004,85:47-64.
[15]Derynck R,Zhang YE. Smad-dependent and Smad-independent pathways in TGF-beta family signalling. Nature,2003,425:577-584.
[16]杨雪梅,王兴胜,崔社怀.肌成纤维细胞在肺纤维化中的来源和作用[J].国际病理科学与临床杂志,2008,28(1)：54-59.
[17]Willis BC,duBois RM,Borok Z. Epithelial origin of myofibroblasts during fibrosis in the lung[J]. Proc Am Thorac Soc 2006,3:377-382,
[18]Selman M,Pardo A. The epithelial/fibroblastic pathway in the pathogenesis of idiopathic pulmonary fibrosis[J]. Am J Respir Cell Mol Biol,2003,29:S93-S96.
[19]吕娟,许增禄,仇文颖,等.小鼠实验性肺纤维化上皮细胞-间充质细胞转变及骨桥蛋白的表达[J].解剖学报,2008,39(3)：420-425.
[20]张小燕,郑金旭.转化生长因子-β1诱导人肺上皮细胞E-钙黏蛋白表达的变化[J].苏州大学学报(医学版),2009,29(3)：430-435.
[21]Kim KK,Kugler MC,Wolters PJ,et al. Alveolar epithelial cell mesenchymal transition develops in vivo during pulmonary fibrosis and is regulated by the extracellular matrix[J]. Proc Natl Acad Sci USA,2006,103:13180-13185.
[22]Brigham C.,Willis,Zea Borok. TGF-b-induced EMT:mechanisms and implications for fibrotic lung disease[J]. Am J Physiol Lung Cell Mol Physiol,2007,293:L525-L534.
[23]Morishima Y,Nomura A,Uchida Y,et al. Triggering the induction of myofibroblast and fibrogenesis by airway epithelial shedding[J]. Am J Respir Cell Mol Biol,2001,24:1-11.
[24]L A Borthwick,S M Parker,K A Brougham,et al. Epithelial to mesenchymal cell transition (EMT) and airway remodelling after human lung transplantion[J]. Thorax,2009,64:770-777.
[25]曹志飞,蒋小岗,张洪涛,等.表没食子儿茶素没食子酸酯对博莱霉素致小鼠肺纤维化的干预作用及其机制探讨[J].苏州大学学报(医学版),2010,30(2)：265-268.
[26]Schissel SL,Layne MD.Telomerase, myofibroblasts, and pulmonary fibrosis[J].Am JRespirCellMolBiol;2006,34:520-522.
[27]White ES,Atrasz RG,Hu B,et al.Negative regulation of myofibroblast differentiation by PTEN (Phosphatase and Tensin Homolog Deleted on chromosome 10[J].Am J Respir Crit Care Med,2006,173:112-121.
[28]蔡琳,吴壮,徐军.博莱霉素诱导α平滑肌肌动蛋白Cre重组酶转基因小鼠肺纤维化上皮细胞-间质转分化的研究[J].中国呼吸与危重监护杂志,2009,8(1)：53-56.
[29]BarthK,Reh J,SturrockA,et al. Epithelial vs myofibroblast differentiation in immortal rat lung cell lines-modulating effects of bleomycin[J].Histochem CellBio,l 2005,124(6):453-464.
[30]徐国萍,徐璟达,李海霞,等.TGF-β1诱导的肺泡Ⅱ型上皮细胞向间质细胞转变[J]复旦学报(医学版),2007,34(2)：223-227.
[31]Buhling F.,Waldburg N.,Reisenauer A.,et al. Lysosomal cysteine proteases in the lung:role in protein processing and immunoregulation[J]. Eur Respir J,2004; 23: 620-628.
[32]Hiroshi Hirakawa,Richard A. Pierce,Gulbin Bingol-Karakoc,et al. Cathepsin S Deficiency Confers Protection from Neonatal Hyperoxia-induced Lung Injury [J]. Am J Respir Crit Care Med,2007,176. pp 778-785.
[33]Gilles Lalmanach*,Elisabeth Diot,Emmanuel Godat,et al. Cysteine cathepsins and caspases in silicosis[J]. Biol. Chem.,387,pp.863-870,2006
[34]Stockley RA. Proteases and antiproteases. Novartis Found Symp 2001; 234: 189-199.
[35]Buhling F,Waldburg N.Gerber A,et al. Cathepsin K expression in human lung. Adv Exp Med Biol,2000; 477:281-286.
[36]Buhling F,Christoph Rocken,Frank Brasch,et al. Pivotal Role of Cathepsin K in Lung Fibrosis. AJP June,2004,164:2203-2216.
[37]Houghton,A. M.,Grisolano,J. L.,et al. Macrophage elastase (matrix metalloproteinase-12) suppresses growth of lung metastases. Cancer Res., 2006,66,6149-6155.
[38]Yasuda,Y.,Li,Z.,Greenbaum,et al. Cathepsin v,a novel and potent elastolytic activity expressed in activated macrophages. J. Biol. Chem;2004,279,36761-36770.
[39]Lecaille,F.,Br6mme,D.,Lalmanach,G.. Biochemical properties and regulation of cathepsin K activity. Biochimie;2008,90,208-226.
[40]R. Koslowski,K. Knoch,E. Kuhlisch,et al. Cathepsins in bleomycin-induced lung injury in rat[J]. Eur Respir J,2003; 22:427-435.
[41]Florian Veillard,Fabien Lecaille,Gilles Lalmanach. Lung cysteine cathepsins: Intruders or unorthodox contributors to the kallikrein-kinin system?[J]. The Intern-ational Journal of Biochemistry & Cell Biology;2008,40:1079-1094
[42]Aline Wille,Annegret Gerber,Anke Heimburg,et al. Cathepsin L is involved in cathepsin D processing and regulation of apoptosis in A549 human lung epithelial cells[J]. Biol. Chem.,2004,385,pp.665-670.
[43]Nicol F.Trincheri,Giuseppina Nicotra,Carlo Follo,et al. Resveratrol induces cell death in colorectal cancer cells by a novel pathway involving lysosomal cathepsin D[J]. Carcinogenesis,2007,28:922-931.
[44]Kominami E,Tsukahara T,Hara K,et al. Biosynthesis and processing of lysosomal cysteine proteinases in rat macrophages[J]. FEBS Lett; 1988,231: 225-228.
[45]Peter S.Tang,Melanie E. Taang,Monika Lodyga.et al. Lipopolysaccharide Accelerates Caspase-Independent but Cathepsin B-Dependent Death of Human Lung Epithelial Cells [J]. J. Cell. Physiol.,2006,209:457-467.
[46]Linda E. Broker,Cynthia Huisman,Simone w. Span,et al. Cathepsin B Mediates Caspase-Independent Cell Death Induced by Microtubule Stabilizing Agents in Non-Small Cell Lung Cancet Cells[J].CANCER RESEAPCH; 2004,64:27-30.
[47]李杰平,张平,张书杰,等.实验性肺纤维化大鼠肺组织Cathepsin B表达的动态变化[J].中国现代医学杂志,2008,18(2)：65-68.
[48]李杰平,何平平,于小华,等.大鼠肺纤维化细胞凋亡及Cathepsin B基因变化的关系[J].现代生物医学进展,2007,7(5)：696-698.
[49]Tao Zheng,Min Jong Kang,Kristina Crothers,et al. Role of Cathepsin S-Dependent Epithelial Cell Apoptosis in IFN-y-Induced Alveolar Remeodeling and Pulmonary Emphysema[J].The Journal of Immunology,174:8106-8115;2005.
[50]H. Ling,S. Vamvakas,G. Bush,et al. Suppressing role of transforming growth factor-beta 1 on cathepsin activity in cultured kidney tubule cells[J]. AJP-Renal Physiol; 1995,269:911-917.
[51]Anita Reisenauer,Oliver Eickelberg,Aline Wille,et al. Increased carcinogenic potential of myeloid tumor cells induced by aberrant TGF-b1-signaling and upregulation of cathepsin B[J]. Biol. Chem.,2007,388,pp.639-650.
[52]Karsdal MA,Hjorth P,Henriksen K,et al. Transforming growth factor-beta controls human osteoclastogenesis through the p38 MAPK and regulation of RANK expression[J]. J Biol Chem,2003,278:44975-44987.
[53]Sybille van den Brule,Pierre Misson,Frank Biihling,et al. Overexpression of cathepsin K during silica-induced lung fibrosis and control by TGF-β[J]. Respiratory Research;2005,6:84.
[54]Kolb M,Bonniaud P,Galt T,et al.Differences in the fibrogenic response after transfer of active transforming growth factor-beta 1 gene to lungs of "fibrosis-prone" and "fibrosis-resistant" mouse strains. Am J Respir Cell Mol Biol;2002,27:141-150.
[55]Lasky JA,Ortiz LA,Tonthat B,et al. Connective tissue growth factor mRNA expression is upregulated in bleomycin-induced lung fibrosis. Am J Physiol; 1998,275:L365-L371.
[1]Taskar VS,Coultas DB. Is idiopathic pulmonary fibrosis an encironmental disease? [J]Proc Am Thorac Soc,2006,3:293-298.
[2]Moises Selman,Annie Pardo. Role of epithelial cells in idiopathic pulmonary fibrosis[J]. Proc Am Thorac Soc,2006,3:364-372.
[3]WANG Jin-sheng,ZENG Qing-fu,FENG De-yun,et. Expression and role of Spl in silicon dioxide-stimulated type Ⅱ pneumocytes[J]. Chinese Journal of Clinical and Experimental Pathology,2006,22(6):710-715.
[4]Mora AL,Woods CR,Garcia A,Xu J,Rojas M,Speck SH,Roman J,Brigham KL,Stecenko AA. Lung infection with y-herpesvirus induces progressive pulmonary fibrosis in Th2-biased mice[J]. Am J Physiol Lung Cell Mol Physiol,2005,289: L711-L721.
[5]Andrea P. Malizia,Dominic T. Keating,Sinead M. Smith,Dermot Walls,Peter P. Doran and Jim J. Egan. Alveolar epithelial cell injury with Epstein-Barr virus upregulates TGF-β1 expression[J]. Am J Physiol Lung Cell Mol Physiol,2008,295: L451-L460.
[6]Armaniso MY,Chen JJ,Cogan JD,et al.Telomerase mutations in families with Idiopathic Pulmonary Fibrosis[J].N Engl J Med,2007,356:1317-1326.
[7]Martina Korfei,Clemens Ruppert,Poornima Mahavadi,et al. Epithelial Endoplasmic Reticulum Stress and Apoptosis in Sporadic Idiopathic Pulmonary Fibrosis[J].Am J Respor Crit Care Med,2008,178:839-846.
[8]Faust PL,Kornfeld S,Chirgwin JM. Cloning and sequence analysis of cDNA for human cathepsin D[J]. Proc Natl Acad Sci U S A 1985;82:4910-4.
[9]Fujita H,Tanaka Y,Noguchi Y,Kono A,Himeno M,Kato K. Isolation and sequencing of a cDNA clone encoding rat liver lysosomal cathepsin D and the structure of three forms of mature enzymes[J]. Biochem Biophys Res Commun 1991;179:190-6.
[10]Godbold GD,Ahn K,Yeyeodu S,Lee LF,Ting JP,Erickson AH. Biosynthesis and intracellular targeting of the lysosomal aspartic proteinase cathepsin D[J]. Adv Exp Med Biol 1998;436:153-62.
[11]Glondu M,Liaudet-Coopman E,Derocq D,Platet N,Rochefort H,Garcia M. Down regulation of cathepsin-D expression by antisense gene transfer inhibits tumor growth and experimental lung metastasis of human breast cancer cells[J]. Oncogene 2002;21:5127-34.
[12]Nakanishi H,Amano T,Sastradipura DF,et al. Increased expression of cathepsin E and D in neurons of the aged rat brain and their colocalization with lipofuscin and carboxy-terminal fragments of Alzheimer amyloid precursor protein[J]. Neurochem 1997;68:739-49.
[13]Hae-Ok Byun,Na-Kyung Han,Hae-June Lee.et al. Cathepsin D and Eukaryotic Translation Elongation Factor 1 as Promising Markers of Cellular Senescence[J]. Cancer Res2009; 69(11):4638-47.
[14]Chun Tu,Cesar F. Ortega-Cava,Gengsheng Chen,et al. Lysosomal Cathepsin B Participates in the Podosome-Mediated Extracellular Matrix Degradation and Invasion via Secreted Lysosomes in v-Src Fibroblasts[J]. Cancer Res 2008;68(22):9147-56.
[15]Joyce JA,Hanahan D. Multiple roles for cysteine cathepsins in cancer[J]. Cell Cycle 2004;3:1516-619.
[16]Mohamed MM,Sloane BF. Cysteine cathepsins:multifunctional enzymes in cancer[J]. Nat Rev Cancer,2006;6:764-75.
[17]Jedeszko C,Sloane BF. Cysteine cathepsins in human cancer[J]. Biol Chem 2004;385:1017-27.
[18]Gocheva V,ZengW,Ke D,et al. Distinct roles for cysteine cathepsin genes in multistage tumorigenesis[J]. Genes Dev,2006;20:543-56.
[19]Frank Buhling,Annegret Gerber,Carsten Hackel,et al. Expression of Cathepsin K in Lung Epithelial Cells[J]. Am. J. Respir. Cell Mol. Biol.20:612-619;1999.
[20]Buhling F,Christoph Rocken,Frank Brasch,et al. Pivotal Role of Cathepsin K in Lung Fibrosis. AJP June,2004,164:2203-2216.
[21]Mrigank Srivatava,Kathrin Steinwede,Riku Kiviranta,et al. Overexpression of cathepsin K in mice decrease collagen deposition and lung resistance in response to bleomycin-induced pulmonary fibrosis [J]. Respiratory Research;2008,9:54.
[22]Sybille van den Brule,Pierre Misson,Frank Buhling,et al. Overexpression of cathepsin K during silica-induced lung fibrosis and control by TGF-β[J]. Respiratory Research;2005,6:84.
[2]肖峰,高洁.特发行肺纤维化的治疗进展[J].临床肺科杂志,2007,2(12)：155.
[3]李辉,代媛媛,李国勤.重温肺痿肺痹文献,探讨特发性肺间质纤维化治疗[J].北京中医药,2010,29(11)：839-842.
[4]丁明桥,许朝霞,王鹏.肺间质纤维化的中医发病机制探讨[J].辽宁中医杂志,2009,36(8)：1291-1292.
[5]张燕萍,林琳,王书臣.肺纤通及其拆方对肺间质纤维化模型大鼠Th1/Th2细胞因子的影响[J].江苏中医药,2008,40(7)：78-80.
[6]陈玉柱.尘肺病的辨证论治[J].中医杂志(增刊),2009,50(12)：77-78.
[7]李柏颖.清热解毒澄其源—宋康教授治疗特发性肺纤维化经验介绍[J].浙江中西医结合杂志,2008,18(6)：359-360.
[8]门炜,贾英杰.贾英杰教授辨证治疗放射性肺炎经验[J].现代中西医结合杂志,19(15)：1889-1890.
[9]胡静,郭永洁,刘旭凌,等.凉血活血法对肺纤维化小鼠羟脯氨酸和TGF-β1含量的影响[J].中国中医药信息杂志,2009,16(9)：25-27.
[10]李宇航,黄颖,郭明章,等.清热解毒药物配伍桔梗对COPD大鼠模型病理形态的影响[J].北京中医药大学学报,2008,31(12)：819-822.
[11]郑丰杰,李宇航,王庆国,等.清热解毒药配伍桔梗汤对急性肺损伤大鼠肺核因子Kappa B p65蛋白表达的影响[J].中华中医药杂志(原中国医药学报),2008,23(7)：586-589.
[12]郑丰杰,李宇航,王庆国,等.清热解毒药配伍桔梗汤对急性肺损伤模型大鼠TLR4 mRNA表达的影响[J].北京中医药大学学报,2009,32(9)：594-597.
[13]郑丰杰,李宇航,王庆国,等.清热解毒药配伍桔梗汤对急性肺损伤模型治疗作用的实验观察[J].中华中医药学刊,2008,26(5)：944-946.
[14]杨惠琴,李风森.试论益气活血法治疗肺间质纤维化[J].新疆医科大学学报,2008,31(6)：737.
[15]刘玉庆,刘贵颖,吕英等.肺纤维化的中医治疗探讨[J].中医研究,2006,19(12)：1-2.
[16]翟华强,杨毅,姜楠.益气活血法对肺纤维化大鼠胶原动态变化影响[J].中国公共卫生,2008,24(7)：892-893.
[17]刘秀芳,王炳胜,李凤玉,等.益气活血中药对放射损伤大鼠肺组织TGF-β1和Ⅰ、Ⅲ型胶原合成的影响[J].现代肿瘤医学,2010,18(8)：1477-1480.
[18]赵兰才,何福金,董小霞,等.三参保肺颗粒对慢阻肺合并肺纤维化大鼠肺组织Ⅰ、Ⅲ型胶原及转化生长因子β1表达的影响[J].世界中西医结合杂志,2010,5(4)：305-326.
[19]孙增涛,廉富,魏葆琳.益气活血散结法治疗特发性肺纤维化临床与实验研究[J].辽宁中医杂志,2007,34(7)：865-867.
[20]李辉,李国勤,高荣林,等.益气活血通络法治疗特发性肺间质纤维化气虚血瘀证疗效观察[J].中国中医急症,2008,17(10)：1341-1343.
[21]李辉,李国勤,刘俊玲,等.益气活血通络汤治疗肺间质纤维化临床观察[J].中国中医药信息杂志,2009,16(2)：65-66.
[22]潘芳,王洪.益气破血方治疗气虚血瘀型特发性肺间质纤维化的临床观察[J].北京中医药,2010,29(8)：614-616.
[23]胡超群.益气祛瘀化痰汤对特发性肺纤维化患者健康相关生存质量的影响[J].中医学报,2010,25(147)：288-289.
[24]周继朴,苑惠清.益气活血化痰解毒中药静点与口服联用治疗特发性肺间质纤维化急性期的临床研究[J].中华中医药学刊,2008,26(9)：2074-2076.
[25]谭善忠,刘成海,张炜,等.扶正化瘀方对大鼠纤维化肺组织MMP-2活性与Ⅳ型胶原表达的影响[J].中国中药杂志,2007,32(9)：835-839.
[26]陆雄,叶伟成,刘平,等.扶正化瘀方对博莱霉素诱发大鼠肺间质纤维化的干预作用[J].中医杂志,2006,47(7)：538-540.
[27]杨珂,谭善忠,张炜,等.扶正化瘀方抗肺纤维化的药物配伍作用特点[J].中医杂志,2009,50(8)：732-736.
[28]郑心,张兴彩.间质流膏对特发性肺间质纤维化患者CRP评分的影响[J].山东中医药大学学报,2009,33(6)：497-499.
[29]张燕萍,樊茂蓉,王书臣,等.肺纤平对博莱霉素所致肺纤维化大鼠Ⅰ、Ⅲ型胶原的影响[J].中国中西医结合杂志,2007,27(11)：1013-1015.
[30]谭漪,董滟,董慧君.补虚通络法治疗特发性肺纤维化的临床研究[J].时珍国医 国药,2009,20(3)：713-714.
[31]余维巍,刘晓晴.黄芪对内毒素性急性肺损伤大鼠肝细胞生长因子表达的影响[J].中国中西医结合杂志,2005,12(5)：309.
[32]解珂,陶富盛,房晓云,等.黄芪对急性肺损伤鼠中性粒细胞粘附功能的影响[J].临床麻醉学杂志,2006,22(5)：375.
[33]奚蕾,夏德洪,沈伟生,等.清燥救肺汤加黄芪对放射性肺损伤干预作用及对肿瘤坏死因子-α及内皮素表达影响的研究[J].时珍国医国药,2010,21(2)：339-341.
[34]夏德洪,奚蕾,沈伟生,等.清燥救肺汤加黄芪对放射性肺损伤干预作用及对TGF-β1,IL-1表达的影响[J].中国实验方剂学杂志,2010,16(6)：240-243.
[35]夏德洪,奚蕾,沈伟生,等.黄芪对放射性肺损伤干预作用及对TGF-β1,IL-1表达影响的研究[J].中国中药杂志,2010,35(8)：1079-1081.
[36]彭清,辛建保,苏良平,等.黄芪对肺纤维化大鼠MMP-2和TIMP-1表达的影响[J].华中科技大学学报(医学版),2007,35(1)：35-37.
[37]包海勇,王亚丽,吴国泰,等.当归黄芪醇提物与水提物对实验性大鼠肺纤维化的干预作用[J].中国新药杂志,2010,19(12)：1064-1067.
[38]刘永琦,李金田,李娟,等.黄芪对肺纤维化大鼠血清细胞因子及肺超微结构的影响[J].中国免疫学杂志,2008,24(12)：980-983.
[39]张平,李杰平,于小华,等.黄茂甲戒对实验性肺纤维化大鼠Cathepsin B表达的影响[J].现代生物医学进展,2007,7(6)：860-863.
[40]李亚东博士论文
[41]张亮,韩春姬,李莲姬,等.轮叶党参提取物对酒精性肝损伤的保护作用[J].中国组织工程研究与临床康复,2007,11(29)：5742-5744.
[42]金凤华,胡芳弟,陈相,等.党参不同提取部分活性比较[J].中药材,2009,32(1)：112-114.
[43]许爱霞,张振明,葛斌,等.党参多糖抗衰老作用机制的实验研究[J].中国现代应用药学杂志,2006,23(8)：729-732.
[44]黄丽亚,叶嗣颖.党参注射液上调抗氧化酶表达作用的实验研究[J].中国老年学杂志,2006,26(1)：70-71.
[45]闫彦芳,张壮,韦颖,等.党参总皂苷抗缺氧缺糖再给氧诱导大鼠星形胶质细胞损伤的作用[J].北京中医药大学学报,2006,29(12)：826-829.
[46]柏长青,遆新宇,刘关键,等.党参、黄芪提取物注射液对减轻肺癌患者化疗毒副反应和生存质量影响的研究[J].中国康复医学杂志,200,21(8)：707-709.
[47]柏长青,宋颖芳,王德堂,等.黄芪、党参提取物增强紫杉醇抑制肿瘤血管生成和转移的实验研究[J].细胞与分子免疫学杂志,2008,24(4)：375-377.
[48]李辉,杜志刚,张学华.黄芪党参汤对肺癌术后放、化疗患者外周血bcl-2表达的影响[J].河北中医,2009,31(10)：1453-1455.
[49]黄丽亚,崔显念.党参与首乌等混合注射液上调抗氧化酶表达作用的实验研究[J].时珍国医国药,2006,17(11)：2195-2196.
[50]黄丽亚,叶嗣颖,刘杰书.党参与天麻对氟哌啶醇致老化大鼠抗氧化酶表达作用的比较研究[J].时珍国医国药,2006,17(9)：1687-1688.
[51]慕桂娟.甘草化学成分的研究进展[J].包头医学2005,29(2)：25-27.
[52]杨莉,陈海霞,高文远,等.甘草抗肿瘤活性成分的研究[J].天然产物研究与开发2009,21(3)：438-440.
[53]何燕,丁维俊,邓国忠,等.肺纤维化模型鼠MMP/TIMP基因表达异常及复方甘草酸苷的调控机制研究[J].现代中西医结合杂志,2008,17(30)：4681-468
[54]何燕,丁维俊,邓国忠,等.复方甘草酸苷对肺纤维化模型大鼠Smad家族基因表达的调控作用研究[J].中国药房,2009,20(19)：1454-1456.
[55]吕小华,吴铁,覃冬云.甘草酸对肺纤维化模型大鼠羟脯氨酸、玻璃酸、层粘连蛋白的干预作用[J].中国药房,2008,19(25)：1954-1955.
[56]叶进燕,陈少贤,谢于鹏,等.甘草甜素抑制肺纤维化大鼠肺组织单核细胞趋化蛋白-1的表达[J].中国病理生理杂志,2007,23(5)：1019-1021.
[57]叶进燕,陈少贤,徐红蕾,等.甘草甜素对大鼠肺纤维化的干预作用及对转化生长因子表达的影响[J].中华结核和呼吸杂志,2006,29(9)：636-637.
[58]丁旭春,王新华,王真.复方甘草甜素治疗博莱霉素致肺纤维化大鼠的研究[J].现代中西医结合杂志,2008,17(27)：4237-4239.
[59]王新华,丁旭春,王真.复方甘草甜素对博莱霉素致肺纤维化大鼠的实验研究[J].中华中医药学刊,2008,26(12)：2628-2630.
[60]李江,武芳,黄茂,等.川芎嗪注射液对博莱霉素致肺纤维化大鼠转化生长因子干预作用的研究[J].时珍国医国药,2007,18(6)：1882-1883.
[61]李江,武芳,黄茂,等.川芎嗪对肺纤维化大鼠Ⅲ型胶原及层黏连蛋白的干预作用[J].实用儿科杂志,2007,22(4)：290-291.
[62]李江,武芳,黄茂,等.川芎嗪对博莱霉素致肺纤维化大鼠病理形态学及细胞外基质的干预作用[J].中华中医药杂志,2007,22(9)：613-614.
[63]王浴生,邓文龙,薛春生.中药药理与应用.第2版.人民卫生出版社,1998：895
[64]谭敏,宾晓农,吴万垠等.莪术油对小鼠肝癌细胞原位凋亡的影响[J].中西医结合肝病杂志,2002,12(5)：290-291.
[65]吴万垠,罗云坚,程剑华等.莪术油对小鼠肝癌细胞DNA作用的图像分析[J].中西医结合肝病杂志,1999,9(1)：18.
[66]Zhu Qingjing,Xiong Zhenfang,Yang Lin. Effects of β-elemene on the expression of Bcl-2 family in hepatic stellate cells[J]. Chin J Integr Trad West Med Dig,2007,15(3):151-155.
[67]Tang Yuan,Li Xiaohui,Inhibitory efects of Zedoray Rhizome abstracts on hepatic cell line HepG2 and their mechanisms. Chinese Pharmacological Bulletin 2007,23(6):790-794.
[68]Fang Ning,Chen Daixiong,Wan Haiyan. Early apoptosls of mice hepatoma HcaF cells induced by β-elemel[J]. Gui Zhou Medleal Journal.2001,25(12):1061-1062.
[69]张维彬,谭敏,肖刚等.莪术油诱导小鼠HepA肝癌细胞凋亡及其对bcl-2蛋白表达的影响.现代中西医结合杂志,2009,18(4)：370-371.
[70]王娟,王顺启,倪虹等.莪术挥发油抑制人肝癌细胞株SMMC-7721生长的实验研究.天津中医药,2003,20(1)：48-50.
[71]吴万垠,郭伟剑,常钢.莪术油微球释放莪术油对人肝癌SM MC-7721细胞的作用.世界华人消化杂志,2003,11(3)：260-263.
[72]Jiang Yuan,Li Zesong,Jiang Fusheng,et al. Influence of curcumol on gene expression of cultured HSC-T6 cells with DNA microarray[J]. Chin J Integr Trad West Med Dig,2005,13(3):144-147.
[73]宋利琼,张昌菊.莪术油联合干扰素对小鼠宫颈癌端粒酶活性和细胞凋亡的影响.上海中医药杂志,2006,40(7)：68-69.
[74]Chen Guang,Ding Xiaofei,Xiao Jinfang,et al. Experimental studies on apoptosis induced by B-elemene derivate in HeLa cells[J]. Chinese Pharmacological Bulletin,2007,23(2):246-250.
[75]刘明远,张春斌,候霞等.榄香烯诱导人卵巢癌细胞COC1细胞凋亡的研究[J].中国临床医芮研究杂志,2003,98：9933-9934.
[76]李传伟,徐英萍,苗芳等.莪术油抗小鼠结肠癌效应的实验研究.泰山医学院学报,2005,26(2)：89-91.
[77]Huang Fuchun,Fan Yu,Zheng Shu. Efect of Elemene on the Telomerase Activity Apoptosis and Cell Cycles of the Colon Can cer Lovo Cell Line[J]. Herald of Medicine,2004,23(10):712-714.
[78]Huang Fuchun,Fan Yu,Lin Gengjin,et al. Fudan Univ J Med Sc,2003,30(1):49-51.
[79]吴冬梅,杨荣宁.莪术油对鼻咽癌CNE-2细胞的凋亡及放疗增敏机制的影响[J].肿瘤防治研究,2008,25(11)：778-781.
[80]刘跃明,孙立群,王义.榄香烯诱导Hep-2细胞凋亡及其对细胞周期各时相的影响[J].中国老年学杂志,2008,28(5)：868-869.
[81]Xu Lichun,Bu Ping,Xu Xiangyu. Experimental Therapeutic Effect of Tumor Cell Vaccine Constructed by Curcumol on Gastric Cancer[J]. Journal of Traditional Chinese Medicine,2007,48(5):450-452.
[82]高鹏,徐立春,陈平等.莪术醇生物构建自体瘤苗治疗晚期胃癌患者近期疗效研究[J].吉林中医药,2008,28(1)：54-58.
[83]徐立春,卜平,陈平等.莪术醇瘤苗生物治疗胃肿瘤13例[J].肿瘤学杂志,2007,13(4)：303-304.
[84]Lu Xian,Xiang Jinfeng. The influence ofβ-elemene on cell cycle and apoptosis of K562 Cells and the investigation of its mechanism[J]. J China Pediatr Blood Cancer,2008,13(4):148-151.
[85]吉庆明.榄香烯对白血病K562细胞中凋亡相关基因PDCD5表达的影响[J]. 中国医药指南,2008,6(3)：16-18
[86]Perl M,Chung CS,Ayala A.Apoptosis[J].Crit Care Med,2005,33:S526-S529.
[87]赵娜,郭治昕,赵雪,等.丹参的化学成分与药理作用[J].国外医药·植物药分册,2007,22(4)：155-160.
[88]赵宗江,刘昆,张迎雪,等.异病同治和同病异治理论在多器官纤维化中的运用[J].中医杂志,2005,46(10)：727-729.
[89]董静,罗桂林,苗维纳,等.丹参对实验性肺纤维化小鼠病理变化和核因子KB表达的影响[J].中国药理学通报,2003,19(12)：1428-1431.
[90]莫晓能,陈文彬.丹参防治肺动脉高压的研究[J].中国中西医结合杂志,1999,19(4)：252-253.
[91]沙莉,郭锡熔,余章斌.丹参对高体积分数氧致新生大鼠支气管肺发育不良的影响[J].实用儿科临床杂志,2008,23(6)：446-448.
[92]施昌礼,李秋根.丹参对矽肺肺纤维化的实验研究[J].中外医疗,2008,14：20-21.
[93]王作刚,甘卉.麦门冬、丹参对肺纤维化大鼠肺组织SOD、MDA、Hyp的影响[J].中国误诊学杂志,2009,9(34)：8347-8348.
[94]林军,冯一中,顾振纶,等.丹参总酚酸对博莱霉素致肺纤维化小鼠的治疗作用[J].中草药,2009,39(3)：400-403.
[95]陆海英,周娟,陆敏,等.丹参酚酸B对实验性肾间质纤维化大鼠的保护作用及其机制[J].中药材,2010,33(11)：1755-1759.
[96]周娟,张悦,陆海英.丹参酚酸B盐对大鼠肾纤维化的影响[J].中国中药杂志,2009,34(21)：2790-2793.
[97]周娟,王飞,陆海英,等.丹参酚酸B盐对TGF-β1诱导的HK-2上皮-间充质转分化的影响[J].中国中药杂志,2010,35(1)：89-93.
[98]李广虎,李志平,徐泳,等.丹参酮ⅡA对放射性肺纤维化防治作用的实验研究[J].中华放射肿瘤学杂志,2006,15(1)：50-54.
[99]孙瑞芳,刘立新,张海燕,等.丹参酮ⅡA对小鼠肝纤维化的干预作用[J].中国中西医结合杂志,2009,29(11)：1012-1017.
[100]李醇文,周亚光,陈娣,等.丹参酮ⅡA对自发性高血压大鼠心肌纤维化的影响中华中医药杂志(原中国医药学报),2010,25(12)：2143-2146.
[101]Literat A, Su F, Norwicki M, et al. Regulation of pro-inflammatory cytokine expression by curcumin in hyaline membrane disease(HMD)[J]. Life Sci,2001,70(3):253.
[102]王建军,王三萍,熊海金,等.姜黄素对哮喘大鼠气道炎症与KB表达的影响[J].中国临床康复,2005,9(11)：102.
[103]姜黄素对哮喘大鼠气道胶原沉积及转化生长因子p1表达的影响[J].临床儿科杂志,2005,23(9)：659-661.
[104]解克芳,牛建昭,王继峰,等.姜黄素对人胚肺成纤维细胞的生长抑制及细胞外基质合成的影响[J].医学研究生学报,2008,21(4)：339-342.
[1]F. BU hling,N. Waldburg,A. Reisenauer,et al. Lysosomal cysteine proteases in the lung:role in protein processing and immunoregulation[J]. Eur Respir J 2004; 23: 620-628.
[2]Gilles Lalmanach,Rlisabeth Diot,Emmanuel Godat,et al. Cysteine cathepsins and caspases in silicosis[J].Biol. Chem.,2006,387:863-870.
[3]Ebisui C,Tsujinaka T,Morimoto T,et al. Interleukin-6 induces proteolysis by activating intracellular proteases (cathepsins B and L,proteasome) in C2C12 myotubes. Clin Sci 1995; 89:431-439.
[4]Li Q,Bever CTJ. Gamma interferon induced increases in intracellular cathepsin B activity in PMA primed THP-1 cells are blocked by inhibitors of protein kinase C. Immunopharmacol Immunotoxicol 1996; 18:375-396.
[5]Ling H,Vamvakas S,Busch G,et al. Suppressing role of transforming growth factor-b1 on cathepsin activity in cultured kidney tubule cells. Am J Physiol 1995; 269:F911-F917.
[6]Lugering N,Kucharzik T,Stein H,et al. IL-10 synergizes with IL-4 and IL-13 in inhibiting lysosomal enzyme secretion by human monocytes and lamina propria mononuclear cells from patients with inflammatory bowel disease. Dig Dis Sci 1998; 43:706-714.
[7]Watari M,Watari H,Nachamkin I,Strauss JF. Lipopolysaccharide induces expression of genes encoding proinflammatory cytokines and the elastin degrading enzyme,cathepsin S,in human cervical smooth-muscle cells. J Soc Gynecol Investig 2000; 7:190-198.
[8]Li Q,Falkler WAJ,Bever CTJ. Endotoxin induces increased intracellular cathepsin B activity in THP-1 cells. Immunopharmacol Immunotoxicol 1997; 19:215-237.
[9]Billington CJ,Mason P,Magny MC,Mort JS. The slowbinding inhibition of cathepsin K by its propeptide. Biochem Biophys Res Commun 2000; 276:924-929.
[10]Bromme D,Li ZQ, Barnes M,Mehler E. Human cathepsin V functional expression,tissue distribution,electrostatic surface potential,enzymatic characterization,and chromosomal localization. Biochemistry 1999; 38:2377-2385.
[11]Lennon-Dumenil AM,Roberts RA,Valentijn K,et al. The p41 isoform of invariant chain is a chaperone for cathepsin L. EMBO J 2001; 20:4055-4064.
[12]Ni J,Fernandez MA,Danielsson L,et al. Cystatin F is a glycosylated human low molecular weight cysteine proteinase inhibitor. J Biol Chem 1998; 273:4797-24804.
[13]Lennon-Dumenil AM,Bakker AH,Maehr R,et al. Analysis of protease activity in live antigen-presenting cells shows regulation of the phagosomal proteolytic contents during dendritic cell activation. J Exp Med 2002; 196:529-540.
[14]Schick C,Bro¨mme D,Bartuski AJ,Uemura Y,Schechter NM,Silverman GA. The reactive site loop of the serpin SCCA1 is essential for cysteine proteinase inhibition. Proc Natl Acad Sci USA 1998; 95:13465-13470.
[15]Levicar N,Strojnik T,Kos J,Dewey RA,Pilkington GJ,Lah TT. Lysosomal enzymes,cathepsins in brain tumour invasion. J Neurooncol 2002; 58:21-32.
[16]程谦,赵久阳.激肽系统与糖尿病肾病关系研究进展[J].国外医学泌尿系统分册,2005,25(4)：569-571.
[17]Mio,T.,Liu,X.,Toews,M. L.,Adachi,et al. Bradykinin augments fibroblast-mediated contraction of released collagen gels. Am. J. Physiol. Lung Cell Mol. Physiol.,2001;281,L164-L171.
[18]Puzer,L.,Vercesi,J.,Alves,M. F.,Barros,N. M.,Araujo,M. S.,Aparecida Juliano,M.,et al. A possible alternative mechanism of kinin generation in vivo by cathepsin L. Biol. Chem.,2005,386,699-704.
[19]Florian Veillard,Fabien Lecaille,Gilles Lalmanach. Lung cysteine cathepsins: Intruders or unorthodox contributors to the kallikrein-kinin system?[J] The International Journal of Biochemistry & Cell Biology,2008; 40:1079-1094.
[20]罗敏琪,林妙霞,曹宝华,等.肝病患者血清胱抑素C与肝纤维化的关系[J].中国自然医学杂志,2010,12(4)：260-262.
[21]Cheng XW,Kuzuya M,Nakamura K,et al. Localization of cysteine protease,cathepsin S,to the surface of vascular smooth muscle cells by association with integrin alphanubeta3[J].Am JPathol,2006,168(2):685-694.
[22]Shi GP,Sukhova GK,Grubb A,Ducharme A,Rhode LH,Lee RT,Ridker PM,Libby P,Chapman HA. Cystatin C deficiency in human atherosclerosis and aortic aneurysms. J Clin Invest.1999; 104:1191-1197.
[23]Satu Helske,Suvi Syvaranta,Ken A. Lindstedt,ea al. Increased Expression of Elastolytic Cathepsins S,K,and V and Their Inhibitor Cystatin C in Stenotic Aortic Valves[J]. Arterioscler Thromb Vasc Biol,2006; 26:1791-1798.
[24]Satpal Ahuja,Poonam Ahuja-Jensen,Leif E. Johnson,et al. rd1 Mouse Retina Shows an Imbalance in the Activity of Cysteine Protease Cathepsins and Their Endogenous Inhibitor Cystatin C[J]. Invest. Ophthalmol. Vis. Sci.,2008; 49:1089-1096.
[25]Barrett D G,Catalano J G,Deaton D N,el al. Orally bioavailable sm all molecule ketoamide based inhibitors of cathepsin K [J]. Bioorg Med Chem Lett,2004;14 (10): 254.
[26]王敏,张月琴.以组织蛋白酶K为靶点的新药筛选[J].中国抗生素杂志,2005,30(6)：373-379.
[27]曾广智,谭宁华,贾锐锐等.组织蛋白酶及其抑制剂研究进展[J].云南植物研究[J].2005,27(4)：337-354
[28]贾锐锐,曾广智,谭宁华,等.组织蛋白酶B的新型天然抑制剂[J].云南植物研究2008,30(5)：621-623.
[29]William P. Daley,Sarah B. Peters,Melinda Larsenl. Extracellular matrix dynamics in development and regenerative medicine[J]. Journal of Cell Science,2008,121:255-264.
[30]Frank Buhling,Christoph Rocken,Frank Brasch,et. Pivotal Role of Cathepsin K in Lung Fibrosis[J]. Am J Pathol,2004; 164:2203-2216.
[31]谢德鄂,孙兵,陈季武.半胱氨酸组织蛋白酶与免疫调节[J].生命的化学,2006,26(3)：229-230.
[32]R.Koslowski,K.Knoch,E.Kuhlisch,et. Cathepsins in bleomycin-induced lung injury in rat[J]. Eur Respir J,2003; 22:427-435.
[33]Perl M,Chung CS,Ayala A. Apoptosis.Crit Care Med,33:S526-S529,2005.
[34]French LE,Tschopp J.Protein-based therapeutic approachestargeting death receptors[J]. Cell Death Differ,2003;10:117-123.
[35]Wajant H.Death receptors[J]. Essays Biochem,2003;39:53-71.
[36]MANI CHOPRA,JAYNE S. REUBEN,AVADHESH C. SHARMA Acute Lung Injury:Apoptosis and Signaling Mechanisms [J]. Exp Biol Med,2009;234:361-371.
[37]Peter S. Tang,Marco Mura,Rashmi Seth. Acute lung injury and cell death:how many ways can cells die[J]? Am J Physiol Lung Cell Mol Physiol,2008;294: L632-L641.
[38]Aline Wille,Annegret Gerber,Anke Heimburg,et al. Cathepsin L is involved in cathepsin D processing and regulation of apoptosis in A549 human lung epithelial cells[J]. Biol. Chem.,2004;385:665-670.
[39]Marina Demoz,Roberta Castino,Patrizia Cesaro,et al. Endosomal-Lysosomal Proteolysis Mediates Death Signalling by TNFa,Not by Etoposide,in L929 Fibrosarcoma Cells:Evidence for an Active Role of Cathepsin D[J]. Biol. Chem.,2002;383:1237-1248.
[40]Heide Schmid,Ramona Sauerbrei,Gerold Schwarz,et al. Modulation of the Endosomal and Lysosomal Distribution of Cathepsins B,L and S in Human Monocytes/Macrophages[J]. Biol. Chem.,2002;383:1277-1283.
[41]Ying Wang,Rebecca M. Baron,Guangli Zhu,et al. PU.1 Regulates Cathepsin S Expression in Professional APCs[J]. The Journal of Immunology,2006,176: 275-283.
[42]Faust PL,Kornfeld S,Chirgwin JM. Cloning and sequence analysis of cDNA for human cathepsin D[J].Proc Natl Acad Sci U S A 1985;82:4910-4.
[43]Fujita H,Tanaka Y,Noguchi Y,Kono A,Himeno M,Kato K. Isolation and sequencing of a cDNA clone encoding rat liver lysosomal cathepsin D and the structure of three forms of mature enzymes[J].Biochem Biophys Res Commun 1991;179:190-6.
[44]Godbold GD,Ahn K,Yeyeodu S,Lee LF.Ting JP,Erickson AH. Biosynthesis and intracellular targeting of the lysosomal aspartic proteinase cathepsin D[J].. Adv Exp Med Biol 1998;436:153-62.
[45]Fuse K M,Vetvicka V. Mitogenic function of human pro—cathepsin D:the role of the propeptide[J]. Biochem J,1994; 303:775-780
[46]Glondu M,Liaudet—Coopman E,Derocq D,Platet N,Rochefort H,Garcia M Down—regulation of cathepsin D expression by antisense gene transfer inhibits turn or growth and experimental lung
[47]metastasis of human breast cancer cells. Oncogene 2002;21:5127-5134
[48]Naora H,Montell DJ. Ovarian cancer metastasis:integrating insights from disparate model organisms. Nat Rev Cancer 2005;5:355-366.
[49]Liu Handong,Chen Jian,Zhou Yi,et al.The relationship between the expression of cathepsin D、PCN A and the postoperative recurrence of bening meningiomas[J]. Central China Medical Journal 2006;30:504-505.
[50]Minarowska A,Gacko M,Karwowska A,Minarowski L. Human cathepsin D.Folia Histochem Cytobiol,2008,46(1):23-38.
[51]Warwas M,Taurowska E.Cathepsin D in diagnosis of neoplastic diseases. Postepy Hig Med Dosw,1993,47(4):277-88.
[52]Levicar N,Strojnik T,Kos J,Dewey RA,Plikington GJ,Lah TT. Lysosomal enzymes,cathepsins in brain tumour invasion.J Neuro-Oncol,2002,58:21-32.
[53]Shibata M,Koike M,Waguri S,Zhang G,Koga T,Uchiyama Y. Cathepsin D is specifically inhibited by deoxyribonucleic acids. FEBS Lett.2002,517:281-284.
[54]陈莉萍,杨鹰.组织蛋白酶D mRNA转录和蛋白表达与卵巢癌的关系[J].西南国防医药,2009,19(1)：54-57.
[55]Pardo M,Garcia A,Antrobus R,et al. Biomarker discovcry from uveal melanoma secretomes:identification of gp100 and cathepsin D in patient serum[J]. J Proteome Res,2007,6(7):2802-2811.
[56]Khalkhali EZ,Hendrix MJ. Elucidating the function of secreted maspin: inhibiting cathepsinD-mediated matrix degradation[J]. Cancer Res,2007,67(8): 3535-3539.
[57]Speleman L,Kerrebijn JD,Look MP,et al. Prognostic value of plasmingen activator inhibitor-1 in head and neck squamous cell carcinoma[J]. Head Neck,2007,29(4):341-350.
[58]Deiss LP,Galinka H,Berissi H,Cohen O,. Cathepsin D protease mediates programmed cell death induced by interferon gamma. Eur Mol Biol Org J. 1996,15:3861-3870.
[59]Deiss LP,Galinka H,Berissi H,Cohen O,Kimchi A. Cathepsin D protease mediates programmed cell death induced by interferon gamma,Fas/APO-1 and TNF alpha. EMBO J.1996,15:3861-3870.
[60]Melanie Beaujouin,Emmanuelle Liaudet-Coopman.Cathepsin D overexpressed by cancer cells can enhance apoptosis-dependent chemo-sensitivity independently of its catalytic activity. Adv Exp Med Biol,2008,617:453-461.
[61]Berchem GJ,Glondu M,Gleizes M,Brouillet JP,Garcia M,Liaudet-Coopman E. Cathepsin-D affects multiple steps of tumor progression:proliferation, angiogenesis and apoptosis.Oncogene,2002,51:5951-5955.
[62]Koike M,Shibata M,Ohsawa Y,Nakanishi H,Koga T,kametaka S,Waguri S,Momoi T,Kominami E,Peters Ch,von Figura K,Sftig P,Uchiyama Y. Involvement of two different cell death pathways in retinal atrophy of cathepsin D deficient mice. Moll Cell Neuroscience,2003,22:146-161.
[63]Koslowski R,Knoch K,Wenzel K-W. Proteinases and proteinase inhibitors during the development of pulmonary fibrosis in rat. Clin Chim Acta,1998,271:45-56.
[64]R. Koslowski,K. Knoch,E. Kuhlisch,D. Seidel and M. Kasper.Cathepsins in bleomycin-induced lung injury in rat. Eur Respir J,2003,22:427-435.
[65]Xiaopeng Li,Heather Rayford,Ruijie Shu,Jiaju Zhuang,and Bruce D. Uhal Essential role for cathepsin D in bleomycin-induced apoptosis of alveolar epithelial cells.Am J Physiol Lung Cell Mol Physiol,2004,287:L46-L51.
[66]Inaoka T,Bilbe G,Ishibashi O,et al.Molecular cloning of human cDNA for cathepsin K:Novel cysteine proteinase predominantly expressed in bone.Biochem Biophys Res Commun,1995,206:89-96.
[67]Patil AD,Freyer AJ,Carte B,et al.Haploscleridamine,a novel tryptamine-derived alkaloid from a sponge of the order haplosclerida:an inhibitor of cathepsin k. J Nat Prod,2002,65:628-629.
[68]Lecaille F,Bromme D,Lalmanach G. Biochemical properties and regulation of cathepsin K activity.Biochimie,2008,90:208-226.
[69]Bromme D,Okamoto K,Wang BB,et al.Human cathepsin O2:a matrix protein-degrading cysteine protease expressed in osteoclasts,functional expression of human cathepsin O2 in Spodoptera frugiperda and characterization of the enzyme [J]. J Biol Chem,1996,271 (4):2126-2132.
[70]Garnero P,Borel O,Byrjalsen I,et al.The collagenolytic activity of cathepsin K is unique among mammalian proteinases [J].J Biol Chem,1998,273(48): 32347-32352.
[71]Rieman DJ,Mcclung HA,Dodds RA,et al. Biosynthesis and processing of cathepsin K in cultured human osteoblasts.Bone,2001,28:282-289.
[72]韩峻峰,罗敏Cathepsin K的研究进展[J].国际内分泌代谢杂志,2006,26(2)：125-127.
[73]韩峻峰,尹晓,李晓华,等Cathepsin K在脂肪细胞分化中的表达及作用[J].上海交通大学学报(医学版).2006,126(1)：59-62.
[74]Podgorski I,Linebaugh BE,Sloane BF.Cathepsin K in the bone microenvironment:link between obesity and prostate cancer?. Biochemical Society,2007,35(Pt 4):701-703.
[75]Barb,D.,Pazaitou-Panayiotou,K. and Mantzoros.Adiponectin:a link between obesity and cancer. Expert Opin Investig Drugs.2006,15(8):917-931.
[76]Williams GA,Wang Y,Callon KE,Watson M,Lin JM,el al. In vitro and in vivo effects of adiponectin on bone. Endocrinology,2009,150(8):3603-10.
[77]Sasaki T,Gohring W,Man K. limited cleavage of ext racellular mat rix protein BM240 by mat rix metalloproteinases increases its affinity for collagens. J Biol Chem,1997,272:9237-9243.
[78]尹晓,陈述林,刘志芬,等.肥胖症患者脂肪组织中组织蛋白酶K的表达及其功能初探[J].中国糖尿病杂志,2008,16(5)：265-266.
[79]Lutgens E,Lutgens SP,Faber BC,et al.Disruption of the cathepsin K gene reduces atherosclerosis progression and induces plaque fibrosis but accelerates macrophage foam cell formation [J].Circulation,2006,113(1):98-107.
[80]刘颖娴,李向平.组织蛋白酶 K与心血管疾病[J].中国动脉硬化杂志,2008,16(1)：75-77.
[81]Turk B Targeting proteases:successes,failures and future prospects. Nat. Rev. Drug Discov,2006;5:785-799.
[82]Morko J,Kiviranta R,Mulari MT,Ivaska KK,Vaananen HK,Vuorio E,Laitala-Leinonen T.Overexpression of cathepsin K accelerates the resorption cycle and osteoblast differentiation in vitro. Bone,2009,44(4):717-28.
[83]吴艳,王毅,杨刚毅.组织蛋白酶K与骨质疏松的研究进展[J].中国骨质疏松杂志,2006,12(5)：522-524.
[84]Konttinen YT,Takagi M,Mandelin J,et al. Acid attack and cathepsin K in bone resorption around total hip replacement prosthesis. J. Bone Miner. Res. 2001;16:1780-1786.
[85]Skoumal M,Haberhauer G,Kolarz G,Hawa G,Woloszczuk W,Klingler A. Serum cathepsin K levels of patients with longstanding rheumatoid arthritis:correlation with radiological destruction. Arthritis Res. Ther.2005;7:R65-R70.
[86]Lecaille F,Bromme D,Lalmanach G. Biochemical properties and regulation of cathepsin K activity. Biochimie.2008;90:208-226.
[87]Mrigank Srivastava,Kathrin Steinwede,el al. Overexpression of cathepsin K in mice decreases collagen deposition and lung resistance in response to bleomycin-induced pulmonary fibrosis. Respiratory Research,2008,9:54
[88]Knaapi J,Lukkarinen H,Kiviranta R,Steiner A,Lassus P,Andersson S,Kaapa P.Cathepsin K expression is diminished in infants with bronchopulmonary dysplasia. Acta Paediatr,2006,95(10):1298-300.
[89]刘剑.组织蛋白酶E氨基端催化性残基的确定[J].中国现代医生,2009,47(20)：1-3.
[90]Zaidi N,Hermann C,Herrmann T,et al.Emerging functional roles of cathepsin E[J].Biochem Biophys Res Commun,2008,377(2):327-330.
[1]王婷,李铁福,林绍强,等.莪术醇的分离鉴定及含量测定[J].中华中医药学刊,2008,26(5)：1018-1021.
[2]杜霞,吴琳华,赵红光.气相色谱-质谱联用测定莪术油中p-榄香烯的含量[J].药物分析杂志,2007,27(2)：216-218.
[3]王建,刘雯,张炜,等.广西不同产地莪术中吉马酮的含量比较[J].时珍国医国药,2009,20(5)：1091-1092.
[4]曹玲,万嵘,王玉.反相高效液相色谱法测定莪术油注射液中莪术醇和栊牛儿酮的含量[J].中国生化药物杂志,2007,28(6)：394-396.
[5]李爱群,胡学军,邓远辉,等.温莪术挥发油的成分[J].中草药,2001,32(9)：782-783.
[6]周欣,李章万,王道平等GC-MS法建立温莪术挥发油指纹图谱研究[J].中国中药杂志,2004,29(12)：1138-1142.
[7]万明珠,梁逸曾,赵晨曦,等.温莪术挥发性化学成分分析和指纹图谱研究[J].时珍国医国药,2009,20(10)：2428-2431.
[8]张慧,孙秀燕,郑艳萍RP-HPLC法分离分析温莪术油中6种倍半萜类成分[J].药物分析杂志,2008,28(12)：1993-1997.
[9]史克莉.不同品种莪术挥发油成分GC-MS分析[J].湖北中医学院学报,2009,11(4)：29-32.
[1]Taskar VS,Coultas DB. Is idiopathic pulmonary fibrosis an encironmental disease?[J] Proc Am Thorac Soc 2006;3:293-98.
[2]Moises Selman,Annie Pardo. Role of epithelial cells in idiopathic pulmonary fibrosis[J]. Proc Am Thorac Soc 2006;3:364-72.
[3]Nagao T,Nagai S,Hiramoto Y,et al. Serial evaluation of high-resolution computed tomography findings in patients with idiopathic pulmonary fibrosis in usual interstitial pneumonia. Respiration,2002,69(5):413-19.
[4]Donald N. Cook,David M. Brass,et al. A Matrix for New Ideas in Pulmonary Fibrosis [J]. Am J Respir Cell Mol Biol,2002,27:122-24.
[5]Nicolas Pottier,Cecule Chupin,Virginie Defamie,et al.Relationships beteeen Early Inflammatory Response to Bleomycin and Sensitivity to Lung Fibrosis[J]Am J Respir Crit Care Med,2007,176:1098-1107.
[6]王响英,吴淑燕,李苏安等.实验性大鼠肺纤维化病理形态及超微结构观察[J].苏州大学学报(医学版),2005,25(3)：379
[7]王浴生,邓文龙,薛春生.中药药理与应用.第2版.人民卫生出版社,1998：895.
[8]宋丽琼,张昌菊.莪术油联合干扰素对小鼠宫颈癌端粒酶活性和细胞凋亡的影响[J].上海中医药杂志,2006,40(7)：68-69.
[9]吴冬梅,杨荣宁.莪术油对鼻咽癌CNE-2细胞的凋亡及放疗增敏机制的影响[J].肿瘤防治研究,2008,35(11)：778-肿瘤防治研究.
[10]唐渊,李晓辉.莪术提取物对肝癌细胞系HepG2的抗癌作用及机制研究[J].中国药理学通报,2007,23(6)：790-794.
[11]张维彬,谭敏,肖刚,等.莪术油诱导小鼠HepA肝癌细胞凋亡及其对bcl-2蛋白表达的影响[J].现代中西医结合杂志,2009,18(4)：370-371.
[12]王娟,王顺启,倪虹,等.莪术挥发油抑制人肝癌细胞株SMMC-7721生长的实验研究[J].天津中医药,2003,20(1)：48-51.
[13]孙增涛,廉富,李小娟,等.肺纤维化模型大鼠肺组织中转化生长因子β1及转化生长因子β1mRNA的表达及黄芪莪术合剂的干预效应[J].中国组织工程研究与临床康复,2007,11(14)：2645-2647.
[14]邱颂平,王英豪,杨素芳.破血化瘀药三棱、莪术对肺纤维化大鼠模型肺形态学及羟脯氨酸的影响[J].福建医科大学学报,2007,41(5)：412-414.
[15]陈贤均,赵红刚.盐制杜仲对小鼠生长发育与脏器系数的影响[J].四川中医,2005,23(11)：29-31.
[16]宋文华,张文佳,张金洋,等.纳米二氧化钛对小鼠肺部生化指标的影响研究[J].南开大学学报(自然科学版),2008,41(3)：14-19.
[17]宋文华,白茹,王雯,等.纳米Ti02材料的环境与健康效应初探[J].南开大学学报(自然科学版),2006,39(6)：41-44.
[18]许祖德,张月娥.陈忠年.博莱霉素诱发大鼠肺纤维化时肺内间质细胞的变化[J].上海医科大学学报,1995,22(2)：93-96.
[19]朱际平,朱海青.肺纤维化大鼠模型肺组织病理超微结构观察及定量分析[J].江苏大学学报(医学版),2007,17(2)：124-127.
[20]陶章,李惠萍.不同剂量博莱霉素致小鼠肺纤维化模型的比较[J].中国组织工程研究与临床康复,2009,13(7)：1214-1218.
[21]袁效涵,黄霞,徐立然,等.不同方剂对肺纤维化模型小鼠的比较研究[J].中成药,2009,31(12)：1827-1829.
[22]Lai CK,Wallace WD,Fishbein MC.Histopathology of pulmonary fibrotic disorders [J].Semin Respir Crit Care Med,2006,27 (6):613-622.
[23]GHOSH A K. Factors involved in the regulation of type I collagen gene9 expression:implication in fibrosis[J]. Exp BiolMed,2002,227(5):301-314.
[24]马跃文,佟振月,侯显明.肺纤维化过程中不同种类胶原异常沉积及分布规律的实验研究[J].中国医科大学学报,2009,38(6)：407-409.
[25]Kim KK,Kugler MC,Wolters PJ,et al.Alveolar epithelial cell mesenchymal transition develops in vivo during pulmonary fibrosis and is regulated by the extracellular matrix [J].Proc Natl Acad Sci USA,2006,103 (35):13180-13185.
[26]Razzaque MS,Hossain MA,Kohno S,et al. Bleomycin-induced pulmonary fibrosis in rat is associated with increased expression of collagen-binding heat shock protein (HSP) 47. Virchows Arch,1998,432(5):455-60.
[27]Endo M,Oyadomari S,Terasaki Y,et al. Induction of arginase Ⅰ and Ⅱ in bleomycin-induced fibrosis of mouse lung. Am J Physiol Lung Cell Mol Physiol, 2003,285(2):L313-21.
[28]Zhang-Hoover J,Sutton A,Stein-Streilein J. CD40/CD40 ligand interactions are critical for elicitation of autoimmune-mediated fibrosis in the lung. J Immunol, 2001,166(5):3556-63.
[29]Nagase T,Uozumi N,Ishii S,et al. A pivotal role of cytosolic phospholipase A(2) in bleomycin-induced pulmonary fibrosis. Nat Med,2002,8(5):480-84.
[30]Hamaguchi Y,Nishizawa Y,Yasui M,et al. Intercellular adhesion molecule-1 and L-selectin regulate bleomycin-induced lung fibrosis. Am J Pathol,2002, 161(5):1607-18.
[31]Van Hoozen BE,Grimmer KL,Marelich GP,et al. Early phase collagen synthesis in lungs of rats exposed to bleomycin. Toxicology,2000,147 (1):1-13.
[1]Kalluri R,Neilson EG. Epithelial-mesenchymal transition and its implications for fibrosis[J]. J Clin Invest,2003,112:1776-1784.
[2]Li Y,Yang J,Dai C,et al. Role for integrin-linked kinase in mediating tubul arepithelial to mesenchymal transition and renal interstitial fibrogenesis[J]. J C lin Invest,2003,112:503-516.
[3]Zavadil J,Bottinger EP. TGF-βand epithelial-to-mesenchymal transitions[J]. Onco Gene,2005,24:5764-5774.
[4]Cheng S,Lovett DH. Gelatinase A (MMP-2) is necessary and sufficient for renal tubular cell epithelial-mesenchymal transformation[J]. Am J Pathol,2003,162: 1937-1949.
[5]Dennler S,Goumans MJ,ten Dijke P. Transforming growth factor-(3signal transduction[J]. J Leukoc Biol,2002,71:731-740.
[6]Sime PJ,O'Reilly KMA. Fibrosis of the lung and other tissues:new concepts in pathogenesis and treatment[J]. Clin Immunol,2001,99:308-319.
[7]Lee JM,Dedhar S,KalluriR,et al. The epithelial-mesenchymal transition:new insights in signaling,development,and disease[J]. J Cell Biol,2006,172(7):973-981.
[8]Zhao J,Shi W,Wang YL,et al. Smad3 deficiency attenuates bleomycin-induced pulmonary fibrosis in mice[J]. Am J Physiol Lung Cell Mol Physiol,2002,282: L585-L593.
[9]Nawshad A,Lagamba D,Polad A,et al. Transforming growth factor-beta signaling during epithelial-mesenchymal transformation:implications for embryogenesis and tumor metastasis[J]. Cells Tissues Organs 2005,179:11-23,
[10]Nawshad A,Lagamba D,Polad A,et al. Transforming growth factor-beta signaling during epithelial-mesenchymal transformation:implications for embryogenesis and tumor metastasis[J]. Cells Tissues Organs,2005,179:11-23.
[11]Thiery JP. Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer,2002,2:442-454.
[12]Kasai H,Allen JT,Mason RM,et al. TGF-1 induces human alveolar epithelial to mesenchymal cell transition (EMT)[J]. Respir Res,2005,6:56.
[13]Willis BC,Liebler JM,Luby-Phelps K,et al. Induction of epithelial-mesenchymal transition in alveolar epithelial cells by transforming growth factor-betal:potential role in idiopathic pulmonary fibrosis[J]. Am J Pathol,2005,166:1321-1332.
[14]Flanders KC. Smad3 as a mediator of the fibrotic response. Int J Exp Pathol,2004,85:47-64.
[15]Derynck R,Zhang YE. Smad-dependent and Smad-independent pathways in TGF-beta family signalling. Nature,2003,425:577-584.
[16]杨雪梅,王兴胜,崔社怀.肌成纤维细胞在肺纤维化中的来源和作用[J].国际病理科学与临床杂志,2008,28(1)：54-59.
[17]Willis BC,duBois RM,Borok Z. Epithelial origin of myofibroblasts during fibrosis in the lung[J]. Proc Am Thorac Soc 2006,3:377-382,
[18]Selman M,Pardo A. The epithelial/fibroblastic pathway in the pathogenesis of idiopathic pulmonary fibrosis[J]. Am J Respir Cell Mol Biol,2003,29:S93-S96.
[19]吕娟,许增禄,仇文颖,等.小鼠实验性肺纤维化上皮细胞-间充质细胞转变及骨桥蛋白的表达[J].解剖学报,2008,39(3)：420-425.
[20]张小燕,郑金旭.转化生长因子-β1诱导人肺上皮细胞E-钙黏蛋白表达的变化[J].苏州大学学报(医学版),2009,29(3)：430-435.
[21]Kim KK,Kugler MC,Wolters PJ,et al. Alveolar epithelial cell mesenchymal transition develops in vivo during pulmonary fibrosis and is regulated by the extracellular matrix[J]. Proc Natl Acad Sci USA,2006,103:13180-13185.
[22]Brigham C.,Willis,Zea Borok. TGF-b-induced EMT:mechanisms and implications for fibrotic lung disease[J]. Am J Physiol Lung Cell Mol Physiol,2007,293:L525-L534.
[23]Morishima Y,Nomura A,Uchida Y,et al. Triggering the induction of myofibroblast and fibrogenesis by airway epithelial shedding[J]. Am J Respir Cell Mol Biol,2001,24:1-11.
[24]L A Borthwick,S M Parker,K A Brougham,et al. Epithelial to mesenchymal cell transition (EMT) and airway remodelling after human lung transplantion[J]. Thorax,2009,64:770-777.
[25]曹志飞,蒋小岗,张洪涛,等.表没食子儿茶素没食子酸酯对博莱霉素致小鼠肺纤维化的干预作用及其机制探讨[J].苏州大学学报(医学版),2010,30(2)：265-268.
[26]Schissel SL,Layne MD.Telomerase, myofibroblasts, and pulmonary fibrosis[J].Am JRespirCellMolBiol;2006,34:520-522.
[27]White ES,Atrasz RG,Hu B,et al.Negative regulation of myofibroblast differentiation by PTEN (Phosphatase and Tensin Homolog Deleted on chromosome 10[J].Am J Respir Crit Care Med,2006,173:112-121.
[28]蔡琳,吴壮,徐军.博莱霉素诱导α平滑肌肌动蛋白Cre重组酶转基因小鼠肺纤维化上皮细胞-间质转分化的研究[J].中国呼吸与危重监护杂志,2009,8(1)：53-56.
[29]BarthK,Reh J,SturrockA,et al. Epithelial vs myofibroblast differentiation in immortal rat lung cell lines-modulating effects of bleomycin[J].Histochem CellBio,l 2005,124(6):453-464.
[30]徐国萍,徐璟达,李海霞,等.TGF-β1诱导的肺泡Ⅱ型上皮细胞向间质细胞转变[J]复旦学报(医学版),2007,34(2)：223-227.
[31]Buhling F.,Waldburg N.,Reisenauer A.,et al. Lysosomal cysteine proteases in the lung:role in protein processing and immunoregulation[J]. Eur Respir J,2004; 23: 620-628.
[32]Hiroshi Hirakawa,Richard A. Pierce,Gulbin Bingol-Karakoc,et al. Cathepsin S Deficiency Confers Protection from Neonatal Hyperoxia-induced Lung Injury [J]. Am J Respir Crit Care Med,2007,176. pp 778-785.
[33]Gilles Lalmanach*,Elisabeth Diot,Emmanuel Godat,et al. Cysteine cathepsins and caspases in silicosis[J]. Biol. Chem.,387,pp.863-870,2006
[34]Stockley RA. Proteases and antiproteases. Novartis Found Symp 2001; 234: 189-199.
[35]Buhling F,Waldburg N.Gerber A,et al. Cathepsin K expression in human lung. Adv Exp Med Biol,2000; 477:281-286.
[36]Buhling F,Christoph Rocken,Frank Brasch,et al. Pivotal Role of Cathepsin K in Lung Fibrosis. AJP June,2004,164:2203-2216.
[37]Houghton,A. M.,Grisolano,J. L.,et al. Macrophage elastase (matrix metalloproteinase-12) suppresses growth of lung metastases. Cancer Res., 2006,66,6149-6155.
[38]Yasuda,Y.,Li,Z.,Greenbaum,et al. Cathepsin v,a novel and potent elastolytic activity expressed in activated macrophages. J. Biol. Chem;2004,279,36761-36770.
[39]Lecaille,F.,Br6mme,D.,Lalmanach,G.. Biochemical properties and regulation of cathepsin K activity. Biochimie;2008,90,208-226.
[40]R. Koslowski,K. Knoch,E. Kuhlisch,et al. Cathepsins in bleomycin-induced lung injury in rat[J]. Eur Respir J,2003; 22:427-435.
[41]Florian Veillard,Fabien Lecaille,Gilles Lalmanach. Lung cysteine cathepsins: Intruders or unorthodox contributors to the kallikrein-kinin system?[J]. The Intern-ational Journal of Biochemistry & Cell Biology;2008,40:1079-1094
[42]Aline Wille,Annegret Gerber,Anke Heimburg,et al. Cathepsin L is involved in cathepsin D processing and regulation of apoptosis in A549 human lung epithelial cells[J]. Biol. Chem.,2004,385,pp.665-670.
[43]Nicol F.Trincheri,Giuseppina Nicotra,Carlo Follo,et al. Resveratrol induces cell death in colorectal cancer cells by a novel pathway involving lysosomal cathepsin D[J]. Carcinogenesis,2007,28:922-931.
[44]Kominami E,Tsukahara T,Hara K,et al. Biosynthesis and processing of lysosomal cysteine proteinases in rat macrophages[J]. FEBS Lett; 1988,231: 225-228.
[45]Peter S.Tang,Melanie E. Taang,Monika Lodyga.et al. Lipopolysaccharide Accelerates Caspase-Independent but Cathepsin B-Dependent Death of Human Lung Epithelial Cells [J]. J. Cell. Physiol.,2006,209:457-467.
[46]Linda E. Broker,Cynthia Huisman,Simone w. Span,et al. Cathepsin B Mediates Caspase-Independent Cell Death Induced by Microtubule Stabilizing Agents in Non-Small Cell Lung Cancet Cells[J].CANCER RESEAPCH; 2004,64:27-30.
[47]李杰平,张平,张书杰,等.实验性肺纤维化大鼠肺组织Cathepsin B表达的动态变化[J].中国现代医学杂志,2008,18(2)：65-68.
[48]李杰平,何平平,于小华,等.大鼠肺纤维化细胞凋亡及Cathepsin B基因变化的关系[J].现代生物医学进展,2007,7(5)：696-698.
[49]Tao Zheng,Min Jong Kang,Kristina Crothers,et al. Role of Cathepsin S-Dependent Epithelial Cell Apoptosis in IFN-y-Induced Alveolar Remeodeling and Pulmonary Emphysema[J].The Journal of Immunology,174:8106-8115;2005.
[50]H. Ling,S. Vamvakas,G. Bush,et al. Suppressing role of transforming growth factor-beta 1 on cathepsin activity in cultured kidney tubule cells[J]. AJP-Renal Physiol; 1995,269:911-917.
[51]Anita Reisenauer,Oliver Eickelberg,Aline Wille,et al. Increased carcinogenic potential of myeloid tumor cells induced by aberrant TGF-b1-signaling and upregulation of cathepsin B[J]. Biol. Chem.,2007,388,pp.639-650.
[52]Karsdal MA,Hjorth P,Henriksen K,et al. Transforming growth factor-beta controls human osteoclastogenesis through the p38 MAPK and regulation of RANK expression[J]. J Biol Chem,2003,278:44975-44987.
[53]Sybille van den Brule,Pierre Misson,Frank Biihling,et al. Overexpression of cathepsin K during silica-induced lung fibrosis and control by TGF-β[J]. Respiratory Research;2005,6:84.
[54]Kolb M,Bonniaud P,Galt T,et al.Differences in the fibrogenic response after transfer of active transforming growth factor-beta 1 gene to lungs of "fibrosis-prone" and "fibrosis-resistant" mouse strains. Am J Respir Cell Mol Biol;2002,27:141-150.
[55]Lasky JA,Ortiz LA,Tonthat B,et al. Connective tissue growth factor mRNA expression is upregulated in bleomycin-induced lung fibrosis. Am J Physiol; 1998,275:L365-L371.
[1]Taskar VS,Coultas DB. Is idiopathic pulmonary fibrosis an encironmental disease? [J]Proc Am Thorac Soc,2006,3:293-298.
[2]Moises Selman,Annie Pardo. Role of epithelial cells in idiopathic pulmonary fibrosis[J]. Proc Am Thorac Soc,2006,3:364-372.
[3]WANG Jin-sheng,ZENG Qing-fu,FENG De-yun,et. Expression and role of Spl in silicon dioxide-stimulated type Ⅱ pneumocytes[J]. Chinese Journal of Clinical and Experimental Pathology,2006,22(6):710-715.
[4]Mora AL,Woods CR,Garcia A,Xu J,Rojas M,Speck SH,Roman J,Brigham KL,Stecenko AA. Lung infection with y-herpesvirus induces progressive pulmonary fibrosis in Th2-biased mice[J]. Am J Physiol Lung Cell Mol Physiol,2005,289: L711-L721.
[5]Andrea P. Malizia,Dominic T. Keating,Sinead M. Smith,Dermot Walls,Peter P. Doran and Jim J. Egan. Alveolar epithelial cell injury with Epstein-Barr virus upregulates TGF-β1 expression[J]. Am J Physiol Lung Cell Mol Physiol,2008,295: L451-L460.
[6]Armaniso MY,Chen JJ,Cogan JD,et al.Telomerase mutations in families with Idiopathic Pulmonary Fibrosis[J].N Engl J Med,2007,356:1317-1326.
[7]Martina Korfei,Clemens Ruppert,Poornima Mahavadi,et al. Epithelial Endoplasmic Reticulum Stress and Apoptosis in Sporadic Idiopathic Pulmonary Fibrosis[J].Am J Respor Crit Care Med,2008,178:839-846.
[8]Faust PL,Kornfeld S,Chirgwin JM. Cloning and sequence analysis of cDNA for human cathepsin D[J]. Proc Natl Acad Sci U S A 1985;82:4910-4.
[9]Fujita H,Tanaka Y,Noguchi Y,Kono A,Himeno M,Kato K. Isolation and sequencing of a cDNA clone encoding rat liver lysosomal cathepsin D and the structure of three forms of mature enzymes[J]. Biochem Biophys Res Commun 1991;179:190-6.
[10]Godbold GD,Ahn K,Yeyeodu S,Lee LF,Ting JP,Erickson AH. Biosynthesis and intracellular targeting of the lysosomal aspartic proteinase cathepsin D[J]. Adv Exp Med Biol 1998;436:153-62.
[11]Glondu M,Liaudet-Coopman E,Derocq D,Platet N,Rochefort H,Garcia M. Down regulation of cathepsin-D expression by antisense gene transfer inhibits tumor growth and experimental lung metastasis of human breast cancer cells[J]. Oncogene 2002;21:5127-34.
[12]Nakanishi H,Amano T,Sastradipura DF,et al. Increased expression of cathepsin E and D in neurons of the aged rat brain and their colocalization with lipofuscin and carboxy-terminal fragments of Alzheimer amyloid precursor protein[J]. Neurochem 1997;68:739-49.
[13]Hae-Ok Byun,Na-Kyung Han,Hae-June Lee.et al. Cathepsin D and Eukaryotic Translation Elongation Factor 1 as Promising Markers of Cellular Senescence[J]. Cancer Res2009; 69(11):4638-47.
[14]Chun Tu,Cesar F. Ortega-Cava,Gengsheng Chen,et al. Lysosomal Cathepsin B Participates in the Podosome-Mediated Extracellular Matrix Degradation and Invasion via Secreted Lysosomes in v-Src Fibroblasts[J]. Cancer Res 2008;68(22):9147-56.
[15]Joyce JA,Hanahan D. Multiple roles for cysteine cathepsins in cancer[J]. Cell Cycle 2004;3:1516-619.
[16]Mohamed MM,Sloane BF. Cysteine cathepsins:multifunctional enzymes in cancer[J]. Nat Rev Cancer,2006;6:764-75.
[17]Jedeszko C,Sloane BF. Cysteine cathepsins in human cancer[J]. Biol Chem 2004;385:1017-27.
[18]Gocheva V,ZengW,Ke D,et al. Distinct roles for cysteine cathepsin genes in multistage tumorigenesis[J]. Genes Dev,2006;20:543-56.
[19]Frank Buhling,Annegret Gerber,Carsten Hackel,et al. Expression of Cathepsin K in Lung Epithelial Cells[J]. Am. J. Respir. Cell Mol. Biol.20:612-619;1999.
[20]Buhling F,Christoph Rocken,Frank Brasch,et al. Pivotal Role of Cathepsin K in Lung Fibrosis. AJP June,2004,164:2203-2216.
[21]Mrigank Srivatava,Kathrin Steinwede,Riku Kiviranta,et al. Overexpression of cathepsin K in mice decrease collagen deposition and lung resistance in response to bleomycin-induced pulmonary fibrosis [J]. Respiratory Research;2008,9:54.
[22]Sybille van den Brule,Pierre Misson,Frank Buhling,et al. Overexpression of cathepsin K during silica-induced lung fibrosis and control by TGF-β[J]. Respiratory Research;2005,6:84.
© 2004-2018 中国地质图书馆版权所有 京ICP备05064691号 京公网安备11010802017129号 地址：北京市海淀区学院路29号 邮编：100083 电话：办公室：(+86 10)66554848；文献借阅、咨询服务、科技查新：66554700 |